Novel anti-hepatitis B virus antibodies and uses thereof

Abstract

Disclosed are anti-hepatitis B surface antigen (HBsAg) antibodies (particularly humanized antibodies), nucleic acid molecules encoding the same, methods for producing the same, and pharmaceutical compositions containing the same. The antibodies have a higher affinity for HBsAg at neutral pH than at acidic pH, thereby significantly increasing the efficiency of viral clearance and extending the duration of viral inhibition. The antibodies and pharmaceutical compositions can be used to prevent and / or treat HBV infection or diseases associated with HBV infection (e.g., hepatitis B), neutralize the toxicity of HBV in a subject (e.g., a human), reduce serum levels of HBV DNA and / or HBsAg in a subject, or activate the humoral immune response of a subject (e.g., a patient with chronic HBV infection or chronic hepatitis B) against HBV.

Description

[Technical field]

[0001] The present invention relates to the field of molecular virology and immunology, in particular to the field of treatment of Hepatitis B Virus (HBV) infection. In particular, the present invention relates to antibodies against Hepatitis B Virus Surface Antigen (HBsAg) and nucleic acids encoding said antibodies, and uses thereof. The anti-HBsAg antibodies of the present invention have a higher binding affinity for HBsAg at neutral pH than at acidic pH. The novel antibodies can be used to prevent and / or treat HBV infection or diseases associated with HBV infection (e.g., Hepatitis B), to neutralize the toxicity of HBV in a subject (e.g., a human), or to reduce serum levels of HBV DNA and / or HBsAg in a subject. Thus, the present invention further relates to the use of the antibodies and variants thereof in the manufacture of a pharmaceutical composition for preventing and / or treating HBV infection or a disease associated with HBV infection (e.g. hepatitis B), neutralizing the toxicity of HBV in a subject (e.g. a human), reducing serum levels of HBV DNA and / or HBsAg in a subject, or activating a humoral immune response against HBV in a subject (e.g. a chronically HBV-infected or chronic hepatitis B patient). [Background technology]

[0002] Hepatitis B virus infection, especially chronic HBV infection, is one of the most important public health problems worldwide (Non-Patent Document 1). Chronic HBV infection may cause a series of liver diseases such as chronic hepatitis B (CHB), liver cirrhosis (LC) and primary hepatocellular carcinoma (HCC) (Non-Patent Document 2). It has been reported that currently, approximately 2 billion people worldwide are infected with HBV, and approximately 350 million people currently have chronic hepatitis B virus infection, and the risk of these infected people ultimately dying from liver disease associated with HBV infection may reach 15% to 25%, with more than 1 million people dying from the disease worldwide every year (Non-Patent Document 1 and Non-Patent Document 2).

[0003] Current therapeutic agents for chronic HBV infection can be divided into interferon (IFN) and nucleoside or nucleotide analogues (NA) (Non-Patent Document 1, Non-Patent Document 3, and Non-Patent Document 2). However, treatment with the above-mentioned drugs alone or in combination cannot completely eliminate the HBV virus in infected individuals, and the success rate of HBsAg negativity or HBsAg seroconversion (evidence of complete HBV virus clearance in infected individuals) is usually less than 5% (Non-Patent Document 3).

[0004] The development of new drugs for the treatment of chronic HBV infection based on immunological means is one of the important research directions in this field. Immunotherapy of chronic HBV infection is usually carried out in two ways: active immunotherapy (its corresponding drug form including vaccines, etc.) and passive immunotherapy (its corresponding drug form including antibodies, etc.). Active immunotherapy refers to the administration of therapeutic vaccines (including protein vaccines, peptide vaccines, nucleic acid vaccines, etc.) to stimulate the body of chronic HBV-infected individuals to actively induce cellular immune responses (such as CTL effects) and / or humoral immune responses (such as antibodies) against HBV, achieving the purpose of inhibiting or eliminating HBV. At present, there is no obviously important and effective active immunotherapy drug / vaccine that can be used for the treatment of chronic HBV infection. Passive immunotherapy (taking antibodies as an example) refers to the administration of antibodies with therapeutic properties to HBV-infected individuals, and the therapeutic effect can be achieved by antibody-mediated virus neutralization, which blocks HBV from infecting neonatal liver cells, or antibody-mediated immune clearance, which removes the virus and infected liver cells from the body. Currently, anti-HBs polyclonal antibodies, i.e. high titer hepatitis B immunoglobulin (HBIG), purified from serum / plasma of patients who responded to prophylactic hepatitis B vaccine or recovered from HBV infection, are widely used to block mother-to-child vertical transmission of HBV, prevent HBV reinfection after liver transplantation in patients with chronic HBV infection, and prevent infection in people accidentally exposed to HBV. However, the direct application of HBIG to treat HBV-infected patients (e.g. CHB patients) has many limitations, such as no obvious efficacy, limited supply of high titer plasma, high cost, unstable nature, and potential safety issues. [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008 Oct 2;359(14):1486-1500 [Non-Patent Document 2] Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009 Feb 14;373(9663): 582-592 [Non-Patent Document 3] Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011 May;8(5): 275-284 Summary of the Invention [Problem to be solved by the invention]

[0006] Therefore, there is an urgent need to develop innovative therapeutic methods and drugs for HBV-infected individuals that can more effectively eliminate the HBV virus, especially HBsAg. [Means for solving the problem]

[0007] The present inventors have previously developed an anti-HBsAg humanized antibody with excellent properties, which can neutralize the toxicity of HBV in vivo and reduce the serum level of HBV DNA and / or HBsAg. Based on the previous research, the present inventors have made many creative efforts and thoroughly studied and modified the humanized antibody to develop an anti-HBsAg antibody with pH-dependent antigen binding ability. The anti-HBsAg antibody of the present invention has a higher affinity for HBsAg at neutral pH than at acidic pH, so that the antibody can be reused, the half-life of the antibody is greatly extended, and the efficiency of HBV clearance is increased. Furthermore, the present inventors introduce mutations into the Fc region of the above-mentioned antibody to increase its affinity for hFcRn or mFcγRII under neutral conditions, thereby obtaining a scavenger antibody and further extending the half-life of the antibody.

[0008] The antibodies of the present invention are highly advantageous because they not only retain the activity of lowering serum levels of HBV DNA and / or HBsAg, but also have a longer period of antigen suppression, thereby significantly reducing the amount of injections and frequency of administration for treatment, and thus have great clinical value.

[0009] Antibodies of the Invention Thus, in one aspect, the present invention provides an antibody, or antigen-binding fragment thereof, capable of specifically binding to HBsAg, which binds to HBsAg with higher affinity at neutral pH than at acidic pH.

[0010] In certain embodiments, the neutral pH is between pH 6.7 and pH 7.5, for example pH 7.4.

[0011] In certain embodiments, the acidic pH is between pH 4.0 and pH 6.5, for example pH 6.0.

[0012] In certain embodiments, the K of an antibody or antigen-binding fragment thereof for binding to HBsAg at acidic pH (e.g., pH 6.0) is D and K for binding to HBsAg at neutral pH (e.g., pH 7.4).D (i.e., K D (acidic pH) / K D (neutral pH) value) is greater than 1, e.g., 1.5 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 15 or more, 20 or more, 30 or more, 40 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, 100 or more, 300 or more, 500 or more, 800 or more, 1000 or more, 2000 or more, 5000 or more, or 10000 or more. D (acidic pH) / K D The value of (neutral pH) is greater than 1 and less than 10,000, for example, less than 5,000, less than 2,000, less than 1,000, less than 900, less than 800, less than 700, less than 600, less than 500, less than 400, less than 300, less than 200, less than 100, less than 90, less than 80, less than 70, less than 60, less than 50, less than 40, less than 30, less than 20, or less than 10. D can be measured by techniques known in the art, such as SPR technology (eg, Biacore).

[0013] In some embodiments, the K of the antibody or antigen-binding fragment thereof for binding to HBsAg at pH 6.0 D and K for binding to HBsAg at pH 7.4 D is greater than 1, e.g., 1.5 or greater, e.g., 2 or greater. In certain embodiments, the K D The value is 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 M, 10 -12 In some embodiments, the K of the antibodies of the invention at acidic pH can be equal to or less than 1 M. D The value is 10 -9 M, 10 -8 M, 10 -7 M, 10 -6 It can be M or more.

[0014] In certain embodiments, the ratio of the EC50 for binding to HBsAg at acidic pH (e.g. pH 6.0) to the EC50 for binding to HBsAg at neutral pH (e.g. pH 7.4) of the antibody or antigen-binding fragment thereof (i.e. the value of EC50(acidic pH) / EC50(neutral pH)) is greater than 1, such as 1.5 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 15 or more, 20 or more, 30 or more, 40 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, 100 or more, 300 or more, 500 or more, 800 or more, 1000 or more, 2000 or more, 5000 or more or 10000 or more. In some embodiments, the value of EC50(acidic pH) / EC50(neutral pH) is greater than 1 and less than 10,000, e.g., less than 5,000, less than 2,000, less than 1,000, less than 900, less than 800, less than 700, less than 600, less than 500, less than 400, less than 300, less than 200, less than 100, less than 90, less than 80, less than 70, less than 60, less than 50, less than 40, less than 30, less than 20, or less than 10. In some embodiments, the EC50 is measured by ELISA and calculated, e.g., by regression analysis of a dose-response curve generated by ELISA.

[0015] In certain embodiments, the ratio of the EC50 for binding to HBsAg at pH 6.0 of the antibody or antigen-binding fragment thereof to the EC50 for binding to HBsAg at pH 7.4 is greater than 1, such as 1.5 or greater, or 2 or greater.

[0016] In certain embodiments, the antibody or antigen-binding fragment thereof of the present invention is derived from the anti-HBV humanized antibody M1D (described in detail in Chinese Patent Application No. 201810307136.5).

[0017] In certain embodiments, the antibodies or antigen-binding fragments thereof of the invention bind to aa 118-124 of HBsAg with higher affinity at neutral pH than at acidic pH.

[0018] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 having one or more of the following characteristics: (i) HCDR1 has at least one amino acid (e.g., 1, 2, 3, 4 or 5 amino acids) replaced with a histidine compared to the sequence set forth in SEQ ID NO:20; (ii) HCDR2 has at least one amino acid (e.g., 1, 2, 3, 4 or 5 amino acids) replaced with a histidine compared to the sequence set forth in SEQ ID NO: 21; and / or (iii) HCDR2 has at least one amino acid (eg, 1, 2, 3, 4 or 5 amino acids) replaced with a histidine compared to the sequence set forth in SEQ ID NO:16.

[0019] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VL) comprising an LCDR1, an LCDR2, and an LCDR3 having one or more of the following characteristics: (i) LCDR1 has at least one amino acid (e.g., 1, 2, 3, 4, or 5 amino acids) replaced with a histidine compared to the sequence set forth in SEQ ID NO:11; (ii) LCDR2 has at least one amino acid (e.g., 1, 2, 3, 4 or 5 amino acids) replaced with a histidine compared to the sequence set forth in SEQ ID NO: 12; and / or (iii) LCDR2 has at least one amino acid (eg, 1, 2, 3, 4 or 5 amino acids) replaced with a histidine compared to the sequence set forth in SEQ ID NO:46.

[0020] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region (VH) comprising the following three CDRs: (i) HCDR1 having the sequence of GGSIX1X2NFW (SEQ ID NO: 50), where X1 is selected from T or H and X2 is selected from S or H; (ii) an HCDR2 having the sequence of X3GX4X5X6X7T (SEQ ID NO: 51), where X3 is selected from S or H, X4 is selected from P, S or Y, X5 is selected from G or D, X6 is selected from T or H, and X7 is selected from Y or H; and (iii)ARSHX8YGX9X 10 DYAFDF (SEQ ID NO:52) (wherein X8 is selected from D or H, X9 is selected from S or H, 10 is selected from H or N, and / or (b) a light chain variable region (VL) comprising the following three CDRs: (iv) QDIX 11 X 12 S (SEQ ID NO:53) (wherein X 11 is selected from S or H, and X 12 is selected from S, Y or H, (v) an LCDR2 having the sequence of YAN (SEQ ID NO: 12); and (vi) QQYHX 13 LPLT (SEQ ID NO:54) (wherein 13 is selected from S or Y, Includes.

[0021] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region (VH) comprising the following three CDRs: (i) HCDR1 consisting of a sequence selected from SEQ ID NOs: 8, 14, 17, and 20; (ii) HCDR2 consisting of a sequence selected from SEQ ID NOs: 9, 15, 21, and 18; and (iii) HCDR3 consisting of a sequence selected from SEQ ID NOs: 10, 16, and 22; and / or (b) a light chain variable region (VL) comprising the following three CDRs: (iv) LCDR1 consisting of a sequence selected from SEQ ID NOs: 11, 19, and 23; (v) LCDR2 consisting of the sequence shown in SEQ ID NO: 12, and (vi) LCDR3 consisting of the sequence shown in SEQ ID NO: 13; Includes.

[0022] In certain embodiments, X1 is selected from T or H, X2 is selected from S, X3 is selected from S, X4 is selected from P or S, X5 is selected from G, X6 is selected from T or H, X7 is selected from Y or H, X8 is selected from D or H, X9 is selected from S or H, and X 10 is selected from H or N, and X 11 is selected from S, and X 12 is selected from S or Y, and X 13 is selected from Y.

[0023] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region (VH) comprising the following three CDRs: (i) HCDR1 consisting of a sequence selected from SEQ ID NOs: 8 and 20; (ii) HCDR2 consisting of a sequence selected from SEQ ID NOs: 9 and 21; and (iii) HCDR3 consisting of a sequence selected from SEQ ID NOs: 10 and 22; and / or (b) a light chain variable region (VL) comprising the following three CDRs: (iv) LCDR1 consisting of a sequence selected from SEQ ID NOs: 11 and 23; (v) LCDR2 consisting of the sequence shown in SEQ ID NO: 12, and (vi) LCDR3 consisting of the sequence shown in SEQ ID NO: 13; Includes.

[0024] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: (1) VH comprising the following three CDRs: HCDR1 as shown in SEQ ID NO: 8, HCDR2 as shown in SEQ ID NO: 9, and HCDR3 as shown in SEQ ID NO: 10; and VL comprising the following three CDRs: LCDR1 as shown in SEQ ID NO: 11, LCDR2 as shown in SEQ ID NO: 12, and LCDR3 as shown in SEQ ID NO: 13. (2) VH comprising the following three CDRs: HCDR1 as shown in SEQ ID NO: 14, HCDR2 as shown in SEQ ID NO: 15, and HCDR3 as shown in SEQ ID NO: 16; and VL comprising the following three CDRs: LCDR1 as shown in SEQ ID NO: 11, LCDR2 as shown in SEQ ID NO: 12, and LCDR3 as shown in SEQ ID NO: 13. (3) VH comprising the following three CDRs: HCDR1 as shown in SEQ ID NO: 20, HCDR2 as shown in SEQ ID NO: 21, and HCDR3 as shown in SEQ ID NO: 22, and VL comprising the following three CDRs: LCDR1 as shown in SEQ ID NO: 23, LCDR2 as shown in SEQ ID NO: 12, and LCDR3 as shown in SEQ ID NO: 13, or (4) VH comprising the following three CDRs: HCDR1 as shown in SEQ ID NO: 17, HCDR2 as shown in SEQ ID NO: 18, HCDR3 as shown in SEQ ID NO: 10, and VL comprising the following three CDRs: LCDR1 as shown in SEQ ID NO: 19, LCDR2 as shown in SEQ ID NO: 12, LCDR3 as shown in SEQ ID NO: 13, Includes.

[0025] In certain embodiments, the antibody or antigen-binding fragment thereof further comprises a human immunoglobulin framework region (e.g., a framework region contained in an amino acid sequence encoded by a human germline antibody gene), which framework region optionally contains one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) back mutations from human residues to murine residues.

[0026] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain framework region comprised in an amino acid sequence encoded by a human heavy chain germline gene and / or a light chain framework region comprised in an amino acid sequence encoded by a human light chain germline gene.

[0027] In certain embodiments, the antibody or antigen-binding fragment thereof is IGHV4-4 * The heavy chain framework region contained in the amino acid sequence encoded by IGKV1-39 (SEQ ID NO:55) * 01 (SEQ ID NO:56), and the heavy chain framework region and / or the light chain framework region optionally contain one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) backmutations from human residues to murine residues.

[0028] In certain embodiments, the VH of the antibody or antigen-binding fragment thereof comprises a VH FR1 set forth in SEQ ID NO:24, a VH FR2 set forth in SEQ ID NO:25, a VH FR3 set forth in SEQ ID NO:26, and a VH FR4 set forth in SEQ ID NO:27.

[0029] In some embodiments, the VL of the antibody or antigen-binding fragment thereof comprises a VL FR1 set forth in SEQ ID NO:28, a VL FR2 set forth in SEQ ID NO:29, a VL FR3 set forth in SEQ ID NO:30, and a VL FR4 set forth in SEQ ID NO:31.

[0030] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region (VH) comprising an amino acid sequence selected from the following: (i) a sequence as set forth in any one of SEQ ID NOs: 1, 3, 4 and 6; (ii) a sequence having one or several amino acid substitutions, deletions or additions (e.g., one, two, three, four or five amino acid substitutions, deletions or additions) compared to the sequence shown in any one of SEQ ID NOs: 1, 3, 4, 6; or (iii) a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to any one of SEQ ID NOs: 1, 3, 4, 6; and, (b) a light chain variable region (VL) comprising an amino acid sequence selected from the following: (iv) a sequence as set forth in any one of SEQ ID NOs: 2, 5, and 7; (v) a sequence having one or several amino acid substitutions, deletions or additions (e.g., one, two, three, four or five amino acid substitutions, deletions or additions) compared to the sequence shown in any one of SEQ ID NOs: 2, 5, 7; or (vi) a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to a sequence set forth in any one of SEQ ID NOs: 2, 5, and 7; Includes.

[0031] In certain embodiments, the substitution described in (ii) or (v) is a conservative substitution.

[0032] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: (1) a VH having a sequence shown in SEQ ID NO: 1 and a VL having a sequence shown in SEQ ID NO: 2; (2) VH having the sequence shown in SEQ ID NO: 3 and VL having the sequence shown in SEQ ID NO: 2; (3) VH having the sequence shown in SEQ ID NO: 4 and VL having the sequence shown in SEQ ID NO: 5, or (4) VH having the sequence shown in SEQ ID NO: 6 and VL having the sequence shown in SEQ ID NO: 7; Includes.

[0033] In certain embodiments, the antibody or antigen-binding fragment thereof further comprises a constant region derived from a human immunoglobulin.

[0034] In certain embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain constant region derived from a human immunoglobulin (e.g., IgG1, IgG2, IgG3, or IgG4) and the light chain of the antibody or antigen-binding fragment thereof comprises a light chain constant region derived from a human immunoglobulin (e.g., κ or λ).

[0035] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: (a) a human immunoglobulin heavy chain constant region (CH) or a variant thereof, which variant has one or more amino acid substitutions, deletions or additions, or any combination thereof, compared to the wild-type sequence from which it is derived (e.g. at most 20, at most 15, at most 10 or at most 5 amino acid substitutions, deletions or additions, or any combination thereof; e.g. 1, 2, 3, 4 or 5 amino acid substitutions, deletions or additions, or any combination thereof); and / or (b) a human immunoglobulin light chain constant region (CL) or a variant thereof, which variant has one or more amino acid substitutions, deletions or additions, or any combination thereof, compared to the wild-type sequence from which it is derived (e.g., at most 20, at most 15, at most 10 or at most 5 amino acid substitutions, deletions or additions, or any combination thereof; e.g., 1, 2, 3, 4 or 5 amino acid substitutions, deletions or additions, or any combination thereof); Includes.

[0036] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a human IgG1 or IgG4 heavy chain constant region. In certain embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain constant region (CH) as set forth in SEQ ID NO:57.

[0037] In certain embodiments, the antibodies or antigen-binding fragments thereof of the invention comprise variants of the heavy chain constant region (CH) of a human immunoglobulin, which variants have enhanced affinity for hFcRn or mFcγRII at neutral pH (e.g., pH 7.4) compared to the wild-type sequence from which they are derived. In such embodiments, the variants generally have at least one amino acid substitution compared to the wild-type sequence from which they are derived.

[0038] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a variant of a human IgG1 heavy chain constant region, the variant having the following substitutions compared to the wild-type sequence from which it is derived: (i) M252Y, N286E, N434Y, or (ii) K326D, L328Y, where the above amino acid positions are according to the Kabat numbering system. In certain embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain constant region (CH) as set forth in SEQ ID NO: 47 or 48.

[0039] In certain embodiments, the light chain constant region is a kappa light chain constant region. In certain embodiments, the antibody or antigen-binding fragment thereof comprises a light chain constant region (CL) as set forth in SEQ ID NO:58.

[0040] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: (1) a heavy chain comprising a VH set forth in SEQ ID NO: 1 and a CH set forth in SEQ ID NO: 57, and a light chain comprising a VL set forth in SEQ ID NO: 2 and a CL set forth in SEQ ID NO: 58; (2) a heavy chain comprising a VH set forth in SEQ ID NO: 1 and a CH set forth in SEQ ID NO: 47, and a light chain comprising a VL set forth in SEQ ID NO: 2 and a CL set forth in SEQ ID NO: 58; (3) a heavy chain comprising VH set forth in SEQ ID NO: 1 and CH set forth in SEQ ID NO: 48, and a light chain comprising VL set forth in SEQ ID NO: 2 and CL set forth in SEQ ID NO: 58; (4) a heavy chain comprising a VH set forth in SEQ ID NO: 3 and a CH set forth in SEQ ID NO: 57, and a light chain comprising a VL set forth in SEQ ID NO: 2 and a CL set forth in SEQ ID NO: 58; (5) a heavy chain comprising a VH set forth in SEQ ID NO: 3 and a CH set forth in SEQ ID NO: 47, and a light chain comprising a VL set forth in SEQ ID NO: 2 and a CL set forth in SEQ ID NO: 58; (6) A heavy chain comprising VH set forth in SEQ ID NO: 3 and CH set forth in SEQ ID NO: 48, and a light chain comprising VL set forth in SEQ ID NO: 2 and CL set forth in SEQ ID NO: 58; (7) A heavy chain comprising VH set forth in SEQ ID NO: 4 and CH set forth in SEQ ID NO: 57, and a light chain comprising VL set forth in SEQ ID NO: 5 and CL set forth in SEQ ID NO: 58; (8) A heavy chain comprising a VH represented by SEQ ID NO: 4 and a CH represented by SEQ ID NO: 47, and a light chain comprising a VL represented by SEQ ID NO: 5 and a CL represented by SEQ ID NO: 58; (9) A heavy chain comprising a VH represented by SEQ ID NO: 4 and a CH represented by SEQ ID NO: 48, and a light chain comprising a VL represented by SEQ ID NO: 5 and a CL represented by SEQ ID NO: 58; (10) A heavy chain comprising VH set forth in SEQ ID NO: 6 and CH set forth in SEQ ID NO: 57, and a light chain comprising VL set forth in SEQ ID NO: 7 and CL set forth in SEQ ID NO: 58; (11) A heavy chain comprising VH set forth in SEQ ID NO: 6 and CH set forth in SEQ ID NO: 47, and a light chain comprising VL set forth in SEQ ID NO: 7 and CL set forth in SEQ ID NO: 58, or (12) A heavy chain comprising VH set forth in SEQ ID NO: 6 and CH set forth in SEQ ID NO: 48, and a light chain comprising VL set forth in SEQ ID NO: 7 and CL set forth in SEQ ID NO: 58; Includes.

[0041] Antibody production The antibody of the present invention can be produced by various methods known in the art, for example, by recombinant genetic engineering. For example, DNA molecules encoding the heavy and light chain genes of the antibody of the present invention can be obtained by chemical synthesis or PCR amplification. The obtained DNA molecules are inserted into an expression vector and then transfected into a host cell. The transfected host cell is then cultured under specific conditions to express the antibody of the present invention.

[0042] The antigen-binding fragments of the present invention can be obtained by hydrolysis of intact antibody molecules (see Morimoto et al., J. Biochem. Biophys. Methods 24:107-117 (1992) and Brennan et al., Science 229:81 (1985)). In addition, these antigen-binding fragments can be produced directly by recombinant host cells (reviewed in Hudson, Curr. Opin. Immunol. 11: 548-557 (1999); Little et al., Immunol. Today, 21: 364-370 (2000)). For example, Fab' fragments can be obtained directly from host cells and chemically coupled to form F(ab')2 fragments (Carter et al., Bio / Technology, 10: 163-167 (1992)). In addition, Fv, Fab or F(ab')2 fragments can be isolated directly from recombinant host cell culture medium. Those of skill in the art will be well aware of other techniques for producing these antigen-binding fragments.

[0043] Thus, in another aspect, the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or antigen-binding fragment thereof, or a heavy and / or light chain variable region thereof of the invention. In certain preferred embodiments, the isolated nucleic acid molecule encodes an antibody or antigen-binding fragment thereof, or a heavy and / or light chain variable region thereof of the invention.

[0044] In another aspect, the invention provides a vector (e.g., a cloning vector or an expression vector) comprising an isolated nucleic acid molecule of the invention. In certain preferred embodiments, a vector of the invention is, for example, a plasmid, cosmid, bacteriophage, etc.

[0045] In another aspect, the present invention provides a host cell comprising the isolated nucleic acid molecule of the present invention or the vector of the present invention. Such host cells include, but are not limited to, prokaryotic cells, such as E. coli cells, and eukaryotic cells, such as yeast cells, insect cells, plant cells, and animal cells (e.g., mammalian cells, such as mouse cells, human cells, etc.). In certain preferred embodiments, the host cell of the present invention is a mammalian cell, such as CHO (e.g., CHO-K1, CHO-S, CHO DG44).

[0046] In another aspect, a method is provided for making an antibody or antigen-binding fragment thereof of the invention, comprising culturing a host cell of the invention under conditions allowing expression of the antibody or antigen-binding fragment thereof, and recovering the antibody or antigen-binding fragment thereof from the cultured host cell culture.

[0047] induced antibody The antibodies or antigen-binding fragments thereof of the present invention can be derivatized, for example, by linking to another molecule (e.g., another polypeptide or protein). Generally, derivatization (e.g., labeling) of the antibodies or antigen-binding fragments thereof does not adversely affect binding to HBsAg. Thus, the antibodies or antigen-binding fragments thereof of the present invention are also intended to include such derivatized forms. For example, the antibodies or antigen-binding fragments of the present invention can be functionally linked (by chemical conjugation, genetic fusion, non-covalent binding or other means) to one or more other molecular groups, such as another antibody (e.g., to form a bispecific antibody), a detection reagent, a pharmaceutical reagent, and / or a protein or polypeptide capable of mediating binding of the antibody or antigen-binding fragment to another molecule (e.g., avidin or polyhistidine tag).

[0048] Thus, in certain embodiments, the antibodies or antigen-binding fragments thereof of the invention are labeled. In some embodiments, the antibodies or antigen-binding fragments thereof of the invention have a detectable label, such as an enzyme, a radionuclide, a fluorochrome, a luminescent material (e.g., a chemiluminescent material), or biotin. A detectable label of the invention can be any material that can be detected by fluorescent, spectroscopic, photochemical, biochemical, immunological, electrical, optical, or chemical means. Such labels are known in the art and examples include enzymes (e.g., horseradish peroxidase, alkaline phosphatase, β-galactosidase, urease, glucose oxidase, etc.), radionuclides (e.g., 3 H, 125 I, 35 S, 14 C or 32 P), fluorescent dyes (e.g., fluorescein isothiocyanate (FITC), fluorescein, tetramethylrhodamine isothiocyanate (TRITC), phycoerythrin (PE), Texas Red, rhodamine, quantum dots or cyanine dye derivatives (e.g., Cy7, Alexa 750)), luminescent substances (e.g., chemiluminescent substances such as acridine ester compounds), magnetic beads (e.g., Dynabeads™), calorimetric markers such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads, and biotin used to ligate avidin (e.g., streptavidin) modified with the above-mentioned markers. In certain embodiments, such labels may be suitable for immunological detection (e.g., enzyme-linked immunoassay, radioimmunoassay, fluorescent immunoassay, chemiluminescent immunoassay, etc.). In certain embodiments, the above-mentioned detectable labels may be ligated to the antibodies or antigen-binding fragments thereof of the present invention by linkers of different lengths to reduce potential steric hindrance.

[0049] Pharmaceutical Compositions and Therapeutic Uses The antibodies or antigen-binding fragments thereof of the invention can be used to prevent or treat HBV infection or a disease associated with HBV infection (e.g., hepatitis B) in a subject (e.g., a human), to neutralize the toxicity of HBV in vitro or in a subject (e.g., a human), to reduce serum levels of HBV DNA and / or HBsAg in a subject (e.g., a human), and to activate a humoral immune response against HBV in a subject (e.g., a patient with chronic HBV infection or chronic hepatitis B).

[0050] Thus, in another aspect, the invention provides a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof of the invention and a pharma- ceutical acceptable carrier and / or excipient. The pharmaceutical composition of the invention may comprise an additional pharma- ceutical active agent. In certain embodiments, the additional pharma- ceutical active agent is a drug used in the prophylaxis or treatment of HBV infection or a disease associated with HBV infection (e.g., hepatitis B), e.g., an interferon drug, such as interferon or pegylated interferon.

[0051] In another aspect, the invention provides use of an antibody or antigen-binding fragment thereof of the invention, or a pharmaceutical composition of the invention, in the manufacture of a medicament for the prevention and / or treatment of HBV infection in a subject (e.g., a human) or a disease associated with HBV infection (e.g., hepatitis B), for neutralizing toxicity of HBV in vitro or in a subject (e.g., a human), for reducing serum levels of HBV DNA and / or HBsAg in a subject (e.g., a human), and / or for activating a humoral immune response against HBV in a subject (e.g., a patient with chronic HBV infection or chronic hepatitis B).

[0052] In another aspect, the present invention provides a method for preventing or treating HBV infection or a disease associated with HBV infection (e.g. hepatitis B) in a subject (e.g. a human), neutralizing toxicity of HBV in vivo or in a subject (e.g. a human), reducing serum levels of HBV DNA and / or HBsAg in a subject (e.g. a human), and / or activating a humoral immune response against HBV in a subject (e.g. a patient with chronic HBV infection or chronic hepatitis B) comprising administering to a subject in need thereof an effective amount of an antibody or antigen-binding fragment thereof according to the invention, or a pharmaceutical composition according to the invention.

[0053] The drugs and pharmaceutical compositions provided by the present invention may be used alone or in combination, and may also be used in combination with other pharmacologic active agents (e.g., other antiviral agents, e.g., interferon drugs such as interferon or pegylated interferon).

[0054] The antibody or antigen-binding fragment thereof of the present invention or the pharmaceutical composition of the present invention can be administered by conventional routes of administration, including, but not limited to, oral, buccal, sublingual, intraocular, topical, parenteral, rectal, intrathecal, intracytoplasmic reticulum, inguinal, intravesical, topical (e.g., powder, ointment or drops), or intranasal routes. The antibody or antigen-binding fragment thereof of the present invention can be administered by a variety of methods known in the art. However, for many therapeutic applications, the preferred route / method of administration is parenteral administration (e.g., intravenous injection, subcutaneous injection, intraperitoneal injection, intramuscular injection). Those skilled in the art will appreciate that the route and / or method of administration will vary depending on the intended purpose. In a preferred embodiment, the antibody or antigen-binding fragment thereof of the present invention is administered by intravenous infusion or injection.

[0055] The antibodies or antigen-binding fragments thereof of the invention or pharmaceutical compositions of the invention can be formulated into a variety of dosage forms, including liquid, semi-solid and solid forms, such as solutions (e.g., injectables), dispersions or suspensions, tablets, powders, granules, emulsions, pills, syrups, powders, liposomes, capsules and suppositories. The preferred dosage form depends on the intended method of administration and therapeutic application.

[0056] For example, one of the preferred dosage forms is an injection. Such an injection may be a sterile injection. For example, a sterile injection can be prepared by the following method: incorporating a required amount of the antibody or its antigen-binding fragment according to the present invention in a suitable solvent, optionally incorporating other expected components (including but not limited to pH adjusters, surfactants, adjuvants, ionic strength enhancers, isotonicity agents, preservatives, diluents or any combination thereof), followed by filtration sterilization. In addition, the sterile injection can be prepared into a sterile powder (for example, by vacuum drying or lyophilization) for easy storage and use. Such a sterile powder can be dispersed in a suitable vehicle such as sterile pyrogen-free water before use.

[0057] Another preferred dosage form is a dispersion. Dispersions can be prepared by the following method: the antibody or antigen-binding fragment thereof according to the present invention is incorporated into a sterile vehicle containing a basic dispersion medium and optionally other desired ingredients (including, but not limited to, pH adjusting agents, surfactants, adjuvants, ionic strength enhancing agents, isotonicity agents, preservatives, diluents, or any combination thereof). In addition, absorption delaying agents such as monostearate salts and gelatin may be incorporated into the dispersion to obtain desired pharmacokinetic properties.

[0058] Another preferred dosage form is an oral solid dosage form including capsules, tablets, powders, granules, etc. Such solid dosage forms generally include at least one of: (a) inert pharmaceutical excipients (or vehicles) such as sodium citrate and calcium phosphate; (b) fillers such as starch, lactose, sucrose, mannose, and silicic acid; (c) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and gum arabic; (d) humectants such as glycerol; (e) disintegrants such as agar-agar, calcium carbonate, potato or tapioca starch; (f) retardants such as olefins; (g) absorption accelerators such as quaternary ammonium compounds; (h) humectants such as cetyl alcohol and glyceryl monostearate; (i) adsorbents such as kaolin and bentonite; (j) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium dodecyl sulfate, or any combination thereof. In the case of tablet and capsule dosage forms, buffering agents may also be included.

[0059] In addition, release rate modifiers (i.e., agents capable of changing the rate of drug release) may be added to the oral solid dosage form to obtain a modified or pulsatile release dosage form. Such release rate modifiers include, but are not limited to, carboxypropylmethylcellulose, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, cellulose acetate, polyethylene oxide, xanthan gum, isoacrylic amino copolymers, hydrogenated aromatic oils, carnauba wax, paraffin, cellulose acetate phthalate, carboxypropylmethylcellulose phthalate, methacrylic acid copolymers, or any combination thereof. A modified or pulsatile release dosage form may include one or a group of release rate modifiers.

[0060] Another preferred dosage form is an oral liquid dosage form, including emulsions, solutions, suspensions, syrups, etc. In addition to the active ingredient, such oral liquid dosage forms may further contain inert solvents commonly used in the art, such as water or other solvents, such as ethyl alcohol, isopropanol, propylene glycol, 1,3-butylene glycol, oils (cottonseed oil, peanut oil, corn oil, olive oil, aromatic oil, sesame oil, etc.), glycerol, polyethylene glycol, and sorbitan fatty acid esters, and any combination thereof. In addition to these inert solvents, such oral liquid dosage forms may further contain moisturizers, emulsifiers, suspending agents, sweeteners, flavoring agents, perfumes, etc.

[0061] In addition, the antibodies or antigen-binding fragments thereof according to the invention may be present in unit dosage form in pharmaceutical compositions for convenient administration. Pharmaceutical compositions according to the invention are preferably sterile and stable under the conditions of manufacture and storage.

[0062] The medicaments and pharmaceutical compositions provided herein may be used alone or in combination, or may be used in combination with additional pharma- ceutical active agents (e.g., other antiviral agents, e.g., interferon or interferon-type agents such as pegylated interferon). In some preferred embodiments, the antibodies or antigen-binding fragments thereof according to the invention are used in combination with other antiviral agent(s) to prevent and / or treat diseases associated with HBV infection. The antibodies or antigen-binding fragments thereof according to the invention and such antiviral agent(s) may be administered simultaneously, separately or sequentially. Such antiviral agent(s) include, but are not limited to, interferon-type agents, ribavirin, adamantane, hydroxyurea, IL-2, L-12, and pentacarboxycytosolic acid.

[0063] A pharmaceutical composition according to the invention may comprise a "therapeutically effective amount" or a "prophylactically effective amount" of an antibody or antigen-binding fragment thereof according to the invention. A "prophylactically effective amount" refers to an amount sufficient to prevent, inhibit or slow the progression of a disease (such as HBV infection or a disease associated with HBV infection). A "therapeutically effective amount" refers to an amount sufficient to cure or at least partially inhibit the disease and its complications in a patient having the disease. A therapeutically effective amount of an antibody or antigen-binding fragment thereof according to the invention may vary depending on the following factors: the severity of the disease to be treated, the overall state of the patient's immune system, the general condition of the patient such as age, weight and sex, the method of administration of the drug, additional therapies used simultaneously, etc.

[0064] Dosage regimens can be adjusted to provide the optimum desired effect (e.g., a therapeutic or prophylactic effect), for example, a single administration can be administered or multiple administrations can be administered over a period of time, or the dose can be proportionally reduced or increased as dictated by the requirements of the therapeutic situation.

[0065] For the antibody or antigen-binding fragment thereof according to the present invention, an exemplary and non-limiting range of a therapeutically or prophylactically effective amount is 0.025 mg / kg to 50 mg / kg, more preferably 0.1 mg / kg to 50 mg / kg, more preferably 0.1 mg / kg to 25 mg / kg, 0.1 mg / kg to 10 mg / kg. It should be noted that the dosage may vary depending on the type and severity of the disease to be treated. In addition, for any particular patient, a specific dosing regimen needs to be adjusted over time depending on the needs of the patient and the professional evaluation by the physician, and it will be understood by those skilled in the art that the dosage ranges presented herein are given for illustrative purposes only, rather than defining the use or scope of the pharmaceutical composition according to the present invention.

[0066] Kits and Detection Applications The antibodies or antigen-binding fragments thereof of the present invention are capable of specifically binding to HBsAg and can therefore be used to detect the presence or level of HBsAg in a sample.

[0067] Thus, in another aspect, the present invention provides a kit comprising an antibody or antigen-binding fragment thereof of the present invention. In some embodiments, the antibody or antigen-binding fragment thereof of the present invention has a detectable label. In other embodiments, the kit further comprises a second antibody that specifically recognizes the antibody or antigen-binding fragment thereof of the present invention. Preferably, the second antibody further comprises a detectable label. Such detectable labels are known to those skilled in the art and include, but are not limited to, radioisotopes, fluorescent substances, luminescent substances, colored substances, and enzymes (e.g., horseradish peroxidase).

[0068] In another aspect, the invention provides a method for detecting the presence or level of HBsAg protein in a sample comprising using an antibody or antigen-binding fragment thereof of the invention. In some embodiments, the antibody or antigen-binding fragment thereof of the invention further comprises a detectable label. In other embodiments, the method further comprises using a second antibody having a detectable label to detect the antibody or antigen-binding fragment thereof of the invention. The method can be used for diagnostic or non-diagnostic purposes (e.g., the sample is not a sample derived from a patient, but is a cell sample).

[0069] In some embodiments, the method comprises: (1) contacting a sample with an antibody or antigen-binding fragment thereof of the invention; and (2) detecting the formation of a complex between the antibody or antigen-binding fragment thereof and HBsAg protein, or detecting the amount of a complex, where the formation of the complex indicates the presence of HBsAg protein and / or HBV.

[0070] In another aspect, the invention provides a method for diagnosing whether a subject is infected with HBV comprising using an antibody or antigen-binding fragment thereof of the invention to detect the presence of HBsAg protein in a sample derived from the subject. In some embodiments, the antibody or antigen-binding fragment thereof of the invention further comprises a detectable label. In other embodiments, the method further comprises using a second antibody bearing a detectable label to detect the antibody or antigen-binding fragment thereof of the invention.

[0071] In another aspect, there is provided the use of an antibody or antigen-binding fragment thereof of the invention in the manufacture of a kit for detecting the presence or level of HBsAg protein in a sample or for diagnosing whether a subject is infected with HBV.

[0072] Definition of Terms In the present invention, unless otherwise specified, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art.In addition, cell culture, biochemistry, nucleic acid chemistry, immunology laboratory and other operation steps used herein are all routine steps widely used in the corresponding fields.In addition, in order to better understand the present invention, the definitions and explanations of related terms are provided below.

[0073] As used herein, the term "antibody" refers to an immunoglobulin molecule that is typically composed of two pairs of polypeptide chains, each pair having a light chain (LC) and a heavy chain (HC). Antibody light chains can be classified as κ (kappa) and λ (lambda) light chains. Heavy chains are classified as μ, δ, γ, α, or ε, and antibody isotypes are defined as IgM, IgD, IgG, IgA, and IgE, respectively. In light and heavy chains, the variable and constant regions are linked by a "J" region of about 12 or more amino acids, and heavy chains also contain a "D" region of about 3 or more amino acids. Each heavy chain is composed of a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region is composed of three domains (CH1, CH2, and CH3). Each light chain is composed of a light chain variable region (VL) and a light chain constant region (CL). The light chain constant region is composed of the domain CL. The constant domains are not directly involved in binding the antibody to an antigen, but exhibit various effector functions, such as mediating the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component of the classical complement system (C1q). The VH and VL regions can also be subdivided into hypervariable regions (called complementarity determining regions (CDRs)) interspersed with relatively conserved regions called framework regions (FRs). Each of the VH and VL is composed of three CDRs and four FRs arranged in the following order from the amino terminus to the carboxy terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of each heavy / light chain pair (VH and VL) form the respective antigen-binding sites. The amino acid assignments in each region or domain may be according to the definitions in Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)) or Chothia & Lesk (1987) J. Mol. Biol. 196:901-917, Chothia et al. (1989) Nature 342:878-883.

[0074] As used herein, the term "complementarity determining region" or "CDR" refers to the amino acid residues in the variable region of an antibody that are involved in antigen binding. Each of the heavy and light chain variable regions contains three CDRs, designated CDR1, CDR2, and CDR3. The exact boundaries of these CDRs can be defined according to various numbering systems known in the art, such as the Kabat numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991), the Chothia numbering system (Chothia & Lesk (1987) J. Mol. Biol. 196:901-917, Chothia et al. (1989) Nature 342:878-883) or the IMGT numbering system (Lefranc et al., Dev. Comparat. Immunol. 27:55-77, 2003). For a given antibody, the CDRs defined by each numbering system can be readily identified by one of skill in the art. Moreover, the correspondence between different numbering systems is known to those of skill in the art (see, e.g., Lefranc et al., Dev. Comparat. Immunol. 27:55-77, 2003).

[0075] In the present invention, the CDRs contained in the antibody or antigen-binding fragment thereof of the present invention can be determined according to various numbering systems known in the art. In certain embodiments, the CDRs contained in the antibody or antigen-binding fragment thereof of the present invention are preferably determined according to the Kabat, Chothia or IMGT numbering system. In certain embodiments, the CDRs contained in the antibody or antigen-binding fragment thereof of the present invention are preferably determined according to the Kabat numbering system.

[0076] As used herein, the term "framework region" or "FR" residues refers to amino acid residues in an antibody variable region other than the CDR residues defined above.

[0077] The term "antibody" is not limited by any particular method of making the antibody. For example, it includes recombinant antibodies, monoclonal antibodies, and polyclonal antibodies. The antibody can be of various isotypes, such as IgG (e.g., IgG1, IgG2, IgG3, or IgG4 subtypes), IgA1, IgA2, IgD, IgE, or IgM antibodies.

[0078] As used herein, the term "antigen-binding fragment" of an antibody refers to a polypeptide comprising a fragment of a full-length antibody that retains the ability to specifically bind to the same antigen bound by the full-length antibody and / or competes with the full-length antibody for specifically binding to an antigen, also referred to as "antigen-binding portion." See generally, Fundamental Immunology, Ch. 7 (Paul, W., ed., 2nd edition, Raven Press, NY (1989), incorporated herein by reference in its entirety for all purposes. Antigen-binding fragments of antibodies can be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Non-limiting examples of antigen-binding fragments include Fab, Fab', F(ab')2, Fd, Fv, complementarity determining region (CDR) fragments, scFv, diabodies, single domain antibodies, chimeric antibodies, linear antibodies, nanobodies (Domantis technology), probodies, and polypeptides comprising at least a portion of an antibody sufficient to confer specific antigen-binding ability to the polypeptide. Engineered antibody variants are reviewed in Holliger et al., 2005; Nat Biotechnol, 23: 1126-1136.

[0079] As used herein, the term "full-length antibody" refers to an antibody composed of two "full-length heavy chains" and two "full-length light chains". A "full-length heavy chain" refers to a polypeptide composed of a heavy chain variable region (VH), a heavy chain constant region CH1 domain, a hinge region (HR), a heavy chain constant region CH2 domain, and a heavy chain constant region CH3 domain in the N-terminal to C-terminal direction. If the full-length antibody is an IgE isotype, it also optionally includes a heavy chain constant region CH4 domain. A "full-length heavy chain" is preferably a polypeptide chain composed of a VH, CH1, HR, CH2, and CH3 in the N-terminal to C-terminal direction. A "full-length light chain" is a polypeptide chain composed of a light chain variable region (VL) and a light chain constant region (CL) in the N-terminal to C-terminal direction. The two pairs of full-length antibody chains are linked by a disulfide bond between the CL and CH1 and a disulfide bond between the HRs of the two full-length heavy chains. The full-length antibody of the present invention may be derived from a single species, such as human, or may be a chimeric or humanized antibody. The full-length antibody of the present invention comprises two antigen-binding sites formed by a VH and VL pair, respectively, and the two antigen-binding sites specifically recognize / bind to the same antigen.

[0080] As used herein, the term "Fd" refers to an antibody fragment consisting of the VH and CH1 domains. The term "dAb fragment" refers to an antibody fragment consisting of the VH domain (Ward et al., Nature 341:544 546 (1989)). The term "Fab fragment" refers to an antibody fragment consisting of the VL, VH, CL and CH1 domains. The term "F(ab')2 fragment" refers to an antibody fragment consisting of two Fab fragments linked by a disulfide bridge on the hinge region. The term "Fab' fragment" refers to a fragment obtained by reducing the disulfide bond linking the two heavy chain fragments in the F(ab')2 fragment and consists of an intact light chain and an Fd fragment of the heavy chain (consisting of the VH and CH1 domains).

[0081] As used herein, the term "Fv" refers to an antibody fragment that is composed of the VL and VH domains of a single arm of an antibody. Fv fragments are generally considered to be the smallest antibody fragment that can form a complete antigen-binding site. It is generally believed that six CDRs confer antigen-binding specificity to an antibody. However, even a single variable region (e.g., an Fd fragment that contains only three antigen-specific CDRs) can recognize and bind an antigen, although the affinity may be lower than that of a complete binding site.

[0082] As used herein, the term "Fc" refers to an antibody fragment formed by linking the second and third constant regions of a first heavy chain and the second and third constant regions of a second heavy chain of an antibody via disulfide bonds. The Fc fragment of an antibody has many different functions, but is not involved in antigen binding.

[0083] As used herein, the term "scFv" refers to a single polypeptide chain comprising a VL and a VH domain, the VL and VH being linked by a linker (see, for example, Bird et al., Science 242:423-426 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Pluckthun, The Pharmacology of Monoclonal Antibodies, Vol. 113, Roseburg and Moore eds, Springer-Verlag, New York, pp. 269-315 (1994)). Such scFv molecules may have the overall structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH. A suitable prior art linker consists of a repeating GGGGS amino acid sequence or a variant thereof. For example, a linker having the amino acid sequence (GGGGS)4 can be used, although variants thereof may also be used (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90: 6444-6448). Other linkers that can be used in the present invention are described in Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur. J. Immunol. 31: 94-106, Hu et al. (1996), Cancer Res. 56:3055-3061, Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56 and Roovers et al. (2001), Cancer Immunol. In some cases, a disulfide bond may also be present between the VH and VL of the scFv.

[0084] As used herein, the term "diabody" refers to a VH and VL domains expressed on a single polypeptide chain, but where the linker used is too short to allow pairing between the two domains on the same chain, one domain is forced to pair with the complementary domain of another chain, creating two antigen-binding sites (see, e.g., Holliger P. et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993) and Poljak RJ et al., Structure 2:1121-1123 (1994)).

[0085] Each of the above-mentioned antibody fragments retains the ability to specifically bind to the same antigen bound by the full-length antibody and / or competes with the full-length antibody for specifically binding to the antigen.

[0086] Antigen-binding fragments of antibodies (e.g., the antibody fragments described above) can be obtained from a given antibody (e.g., an antibody provided by the present invention) using conventional techniques known to those of skill in the art (e.g., recombinant DNA techniques or enzymatic or chemical fragmentation) and screened for specificity in the same manner as intact antibodies are screened.

[0087] As used herein, unless the context clearly indicates otherwise, reference to the term "antibody" includes not only complete antibodies but also antigen-binding fragments of antibodies.

[0088] As used herein, the terms "monoclonal antibody", "McAb" and "mAb" have the same meaning and can be used interchangeably. The term refers to an antibody or antibody fragment from a population of antibody molecules exhibiting a high degree of homology, i.e., a population of antibody molecules that are completely identical except for natural mutations that may occur spontaneously. A monoclonal antibody has high specificity for a single epitope of an antigen. A polyclonal antibody generally contains at least two or more different antibodies that generally recognize different epitopes on an antigen compared to a monoclonal antibody. In addition, the modifier "monoclonal" merely indicates the character of the antibody obtained from a highly homogeneous population of antibodies and should not be construed as requiring production of the antibody by any particular method.

[0089] As used herein, the term "chimeric antibody" refers to an antibody in which a portion of the light or / and heavy chain is derived from one antibody (which may be from a particular species or belong to a particular antibody class or subclass) and another portion of the light or / and heavy chain is derived from another antibody (which may be from the same or a different species or belong to the same or a different antibody class or subclass), but in either case still retains binding activity for the target antigen (U.S. Pat. No. 4,816,567 to Cabilly et al.; Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851 6855 (1984)). For example, the term "chimeric antibody" may include an antibody in which the heavy and light chain variable regions of the antibody are derived from a first antibody (e.g., a mouse antibody) and the heavy and light chain constant regions of the antibody are derived from a second antibody (e.g., a human antibody) (e.g., a human-mouse chimeric antibody). To generate chimeric antibodies, the immunoglobulin variable regions of the immunized animal can be linked to human immunoglobulin constant regions using methods known in the art (see, e.g., U.S. Patent No. 4,816,567 to Cabilly et al.). For example, the DNA encoding the VH is operably linked to another DNA molecule encoding a heavy chain constant region to obtain a full-length heavy chain gene. The sequences of human heavy chain constant region genes are known in the art (see, e.g., Kabat, EA et al. (1991), Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242), and DNA fragments containing these regions can be obtained by standard PCR amplification. The heavy chain constant region can be an IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM or IgD constant region, but is generally preferably an IgG1 or IgG4 constant region. For example, the DNA encoding the VL is operably linked to another DNA molecule encoding the light chain constant region, CL, to provide a full-length light chain gene (and a Fab light chain gene).The sequences of human light chain constant region genes are known in the art (see, e.g., Kabat, EA et al. (1991), Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242), and DNA fragments containing these regions can be obtained by standard PCR amplification. The light chain constant region can be a kappa or lambda constant region, but is generally preferably a kappa constant region.

[0090] As used herein, the term "humanized antibody" refers to a genetically engineered non-human antibody whose amino acid sequence has been modified to increase homology with the sequence of a human antibody. Generally, all or a portion of the CDR regions of a humanized antibody are derived from a non-human antibody (donor antibody) and all or a portion of the non-CDR regions (e.g., variable region FRs and / or constant regions) are derived from a human immunoglobulin (receptor antibody). In some embodiments, the CDR regions of a humanized antibody are derived from a non-human antibody (donor antibody) and all or a portion of the non-CDR regions (e.g., variable region FRs and / or constant regions) are derived from a human immunoglobulin (receptor antibody). A humanized antibody generally retains the expected properties of the donor antibody, including, but not limited to, antigen specificity, affinity, reactivity, etc. The donor antibody can be a mouse, rat, rabbit, or non-human primate (e.g., cynomolgus monkey) antibody with the desired properties (e.g., antigen specificity, affinity, reactivity, etc.). To generate humanized antibodies, the CDR regions of an immunized animal can be inserted into human framework sequences using methods known in the art (see U.S. Pat. No. 5,225,539 to Winter; U.S. Pat. Nos. 5,530,101; 5,585,089; 5,693,762 and 6,180,370 to Queen et al.; and Lo, Benny, KC, editor, in Antibody Engineering: Methods and Protocols, volume 248, Humana Press, New Jersey, 2004).

[0091] As used herein, the term "germline antibody gene" or "germline antibody gene segment" refers to a sequence present in the genome of an organism that encodes an immunoglobulin that has not undergone a maturation process that may result in gene rearrangements and mutations for the expression of a particular immunoglobulin. In the present invention, the expression "heavy chain germline gene" refers to a germline antibody gene or gene fragment that encodes an immunoglobulin heavy chain, including a V gene (variable), a D gene (diversity), a J gene (joining), and a C gene (constant). Similarly, the expression "light chain germline gene" refers to a germline antibody gene or gene fragment that encodes an immunoglobulin light chain, including a V gene (variable), a J gene (joining), and a C gene (constant). In the present invention, the amino acid sequence encoded by a germline antibody gene or germline antibody gene fragment is also referred to as a "germline sequence". Germline antibody genes or germline antibody gene fragments and their corresponding germline sequences are known to those skilled in the art and can be obtained or retrieved from specialized databases (e.g., IMGT, unswag, NCBI, or VBASE2).

[0092] As used herein, the term "specific binding" refers to a non-random binding reaction between two molecules, such as the reaction between an antibody and its antigen. The strength or affinity of a specific binding interaction is determined by the equilibrium dissociation constant (K D In the present invention, "K D The term "antibody-antigen binding constant" refers to the dissociation equilibrium constant of a particular antibody-antigen interaction and is used to describe the binding affinity between an antibody and an antigen. The smaller the equilibrium dissociation constant, the stronger the antibody-antigen binding and the higher the affinity between the antibody and the antigen. The specific binding properties between two molecules can be measured using methods known in the art, for example, using surface plasmon resonance (SPR) in a BIACORE instrument.

[0093] As used herein, the phrase "binds with higher affinity at neutral pH than at acidic pH" or the equivalent phrase "pH-dependent binding" refers to the K D The K value or EC50 value is the K D It means that the activity is higher than the EC50 value. D can be measured by techniques known in the art, such as SPR techniques (e.g., Biacore). In the present invention, the term "EC50" refers to the antibody-antigen half maximum effect concentration, i.e., the antibody concentration required to reach 50% of the maximum binding effect between a particular antibody and antigen, and is used to describe the binding ability between an antibody and an antigen. The smaller the EC50, the higher the binding ability between an antibody and an antigen. The antibody-antigen half maximum effect concentration (EC50) can be determined using techniques known in the art, such as enzyme-linked immunosorbent assay (ELISA), in which an antigen is bound to a solid support and an antibody is specifically bound to the antigen.

[0094] As used herein, a "neutralizing antibody" refers to an antibody or antigen-binding fragment thereof that can significantly reduce or completely inhibit the toxicity (e.g., ability to infect cells) of a target virus. Generally, a neutralizing antibody can recognize and bind to a target virus and prevent the target virus from invading / infecting a subject's cells. The antibody of the present invention is a neutralizing antibody.

[0095] However, in the present application, it should be understood that the virus neutralizing ability of an antibody is not entirely equivalent to the virus clearing ability of an antibody. As used herein, "neutralizing a virus" means neutralizing the toxicity of a target virus by inhibiting the target virus from entering / infecting the cells of a subject (i.e., significantly reducing or completely inhibiting the toxicity of the target virus). As used herein, "clearing a virus" means removing the target virus (whether or not it is infecting cells) from an organism, thereby changing the organism to a state before infection with the virus (e.g., the result of a serological test for the virus becomes negative). Thus, in general, a neutralizing antibody does not necessarily have a virus clearing ability. However, in the present application, the inventor surprisingly found that the antibody according to the present invention can not only neutralize HBV, but also clear the virus (i.e., clear HBV DNA and / or HBsAg in vivo and clear HBV and HBV-infected cells in vivo), and thus has important clinical value.

[0096] As used herein, the term "isolated" refers to a state obtained from a natural state by artificial means. If a particular "isolated" substance or component exists in nature, this is possible because the natural environment has been altered or the substance has been isolated from the natural environment, or both. For example, if a particular non-isolated polynucleotide or polypeptide naturally exists in a particular living animal, the same polynucleotide or polypeptide isolated in high purity from such a natural state is called an isolated polynucleotide or polypeptide. The term "isolated" does not exclude contaminating artificial or synthetic substances, nor other impurities that do not affect the activity of the isolated substance.

[0097] As used herein, the term "vector" refers to a nucleic acid vehicle into which a polynucleotide can be inserted. If the vector allows for the expression of a protein encoded by the inserted polynucleotide, the vector is referred to as an expression vector. The vector can be introduced into a host cell by transformation, transduction or transfection so that the elements of genetic material carried by the vector can be expressed in the host cell. Vectors are known to those skilled in the art and include, but are not limited to, plasmids; phagemids; cosmids; artificial chromosomes such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs) or P1-derived artificial chromosomes (PACs); bacteriophages such as lambda phage or M13 phage, and animal viruses. Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (e.g., herpes simplex viruses), poxviruses, baculoviruses, papilloma viruses, papova viruses (e.g., SV40). The vector may contain various elements that control expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. In addition, the vector may contain a replication origin.

[0098] As used herein, the term "host cell" refers to a cell into which a vector can be introduced, including, but not limited to, prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.

[0099] As used herein, the term "identity" refers to the degree of correspondence between two polypeptides or two nucleic acids. If the two sequences being compared have the same monomer subunit of a base or amino acid at a particular site (e.g., two DNA molecules each have an adenine at a particular site, or two polypeptides each have a lysine at a particular site), then the two molecules are identical at that site. The percent identity between two sequences is a function of the number of identical sites shared by the two sequences times 100 relative to the total number of sites being compared. For example, if 6 out of 10 sites in two sequences are identical, then the two sequences have 60% identity. For example, the DNA sequences: CTGACT and CAGGTT have 50% identity (3 out of 6 sites are identical). Generally, the comparison of two sequences is performed to obtain the maximum identity. Such alignments can be performed using computer programs such as the Align program (DNAstar, Inc.), which is based on the method of Needleman, et al. (J. Mol. Biol. 48:443-453, 1970). The percent identity between two amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4:11-17 (1988)) as incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4. Additionally, the percentage identity between two amino acid sequences can be determined using the algorithm of Needleman and Wunsch (J. Mol. Biol. 48:444-453 (1970)) as incorporated into the GAP program of the GCG software package (available at http: / / www.gcg.com), using a Blossum weight residue table. Either a PAM62 matrix or a PAM250 matrix can be used, with gap weights of 16, 14, 12, 10, 8, 6 or 4 and length weights of 1, 2, 3, 4, 5 or 6.

[0100] The twenty conventional amino acids in the context of this specification are represented in the conventional manner. See, for example, Immunology-A Synthesis (2nd Edition, ES Golub and DR Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference. In this disclosure, the terms "polypeptide" and "protein" have the same meaning and are used interchangeably. Also, in this disclosure, amino acids are generally represented by one-letter and three-letter abbreviations known in the art. For example, alanine can be represented by A or Ala. In addition, as used herein, the terms "monoclonal antibody" and "McAb" have the same meaning and can be used interchangeably. The terms "polyclonal antibody" and "PcAb" have the same meaning and can be used interchangeably.

[0101] As used herein, the term "pharmaceutical acceptable carriers and / or excipients" refers to carriers and / or excipients that are pharmacologically and / or physiologically compatible with the subject and active substance known in the art (see, e.g., Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), including, but not limited to, pH adjusting agents, surfactants, adjuvants, ionic strength enhancing agents, diluents, osmotic pressure control agents, absorption retarding agents, and preservatives. For example, pH adjusting agents include, but are not limited to, phosphate buffers. Surfactants include, but are not limited to, cationic, anionic, or nonionic surfactants, such as Tween-80. Ionic strength enhancers include, but are not limited to, sodium chloride. Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, and sorbic acid. Osmotic pressure control agents include, but are not limited to, sugars, NaCl, and their analogs. Agents that delay absorption include, but are not limited to, monostearate and gelatin.

[0102] As used herein, the term "prevention / preventing" refers to a method performed to inhibit or delay the onset of a disease, disorder or condition in a subject, such as HBV infection or a disease associated with HBV infection. As used herein, the term "treatment / treating" refers to a method performed to obtain a beneficial or desired clinical outcome. For the purposes of the present invention, beneficial or desired clinical outcomes include, but are not limited to, alleviation of symptoms, whether detectable or undetectable, reduction in the extent of disease, stabilization of the disease state (i.e., not worsening), delay or slowing of disease progression, and alleviation of symptoms (either partial or complete). In addition, "treatment" also refers to an increase in survival time compared to expected survival time (in the absence of treatment). In the present application, the antibody according to the present invention has the ability to neutralize HBV and can therefore be used to prevent / protect a non-affected subject or its cells from infection by HBV. In addition, the antibodies according to the invention have the ability to clear HBV (i.e., can clear HBV DNA and / or HBsAg in vivo and can clear HBV and HBV infected cells in vivo) and therefore can be used to treat HBV infection or a disease associated with HBV infection in an infected subject.

[0103] As used herein, the term "subject" refers to a mammal, such as a primate mammal, for example a human.

[0104] As used herein, the term "effective amount" refers to an amount sufficient to achieve or at least partially achieve an expected effect. For example, an amount effective for preventing a disease (such as HBV infection or a disease associated with HBV infection) refers to an amount effective for preventing, inhibiting or delaying the onset of the disease (such as HBV infection or a disease associated with HBV infection). An amount effective for treating a disease refers to an amount effective for curing or at least partially preventing the disease and its complications in a patient having the disease. Determining such an effective amount is within the capabilities of a person skilled in the art. For example, an amount effective for therapeutic use will vary depending on the severity of the disease to be treated, the overall state of the patient's immune system, the general condition of the patient, such as age, weight and sex, the method of administration of the drug, additional therapies used at the same time, etc. Effect of the Invention

[0105] Beneficial Effects of the Invention The antibody of the present invention can specifically recognize / bind to HBsAg, neutralize the toxicity of HBV, reduce the serum level of HBV DNA and / or HBsAg in a subject, and effectively eliminate HBV and HBV-infected cells in the body, as well as have a significantly improved antigen clearance effect and antigen suppression time. Particularly surprisingly, it is known in the art that, although chronic hepatitis B patients tend to have prolonged infection due to immune exhaustion (tolerance) to HBV due to high levels of HBsAg in the body, the antibody of the present invention can increase the clinical cure rate by activating the subject (e.g., chronic HBV-infected patient or chronic hepatitis B patient) to restore humoral immune response to HBV. Therefore, the antibody of the present invention is particularly suitable for the prevention and treatment of HBV infection and diseases associated with HBV infection (e.g., hepatitis B). In addition, the antibody of the present invention has pH-dependent antigen binding properties, and a single molecule of the antibody can bind to multiple molecules of the antigen, so that the administration frequency and dosage can be reduced, which has great clinical value.

[0106] The embodiments of the present invention will be described in detail below in conjunction with the accompanying drawings and examples. However, it is understood by those skilled in the art that the following drawings and examples are only used to explain the present invention, and are not intended to limit the scope of the present invention. Various objects and advantageous aspects of the present invention will become apparent to those skilled in the art through the accompanying drawings and the following detailed description of the preferred embodiments. [Brief description of the drawings]

[0107] [Figure 1] Schematic diagram of the action principle of an antibody with pH-dependent antigen-binding activity. Human plasma is neutral with a pH of about 7.4, while the intracellular environment is acidic with a pH of about 6.0. An antibody with pH-dependent antigen-binding activity can bind to an antigen in the plasma, and the antigen-antibody complex is subsequently internalized into the cell. The pH-dependent antibody dissociates from the antigen in the acidic environment of the endosome. The antibody dissociated from the antigen is captured by FcRn and circulates outside the cell. In the neutral environment outside the cell, FcRn releases the antibody, and the antibody that has returned to the plasma can bind to another antigen again, thus realizing the cycle of antibody use. [Diagram 2] Figure 1 shows a simulation of the three-dimensional structure of the M1D variable region. The stick structures represent the CDR regions, with blue representing the VK CDR, green representing the VH CDR, and red representing surface amino acids. A total of 25 surface amino acids can be seen in the CDR regions. [Diagram 3] Schematic diagram of a recombinant vector (pCGMT-scFv) encoding an scFv antibody, in which the structure of the scFv antibody is NH2-VH-linker-VL-COOH. [Figure 4]4A-4C are diagrams showing the results of ELISA of the pH-dependent scFv antibody derived from M1D and the phage library displaying the antigen HBsAg. FIG. 4A: Detection results of binding to HBsAg at pH 7.4 and pH 6.0 for the phage library of pH-dependent scFv antibody derived from M1D after the third round of screening, where the abscissa represents the phage antibody number or dilution factor, and the ordinate represents the OD value. The results show that all of these single clones have strong antigen binding activity, and the binding activity is greatly reduced at pH 6.0. FIG. 4B: Detection results of pH-dependent binding to HBsAg at eight gradients and three-fold dilutions for six single clones that have high OD (450 / 630) values ​​at pH 7.4 in the third round and show the largest difference in OD (450 / 630) values ​​at pH 7.4 and pH 6.0, where the abscissa represents the dilution factor, and the ordinate represents the OD value. The results show that pH-dependent antigen binding effect is better shown after gradient dilution, among which A31-73 shows the best effect. Figure 4C: Preliminary results of pH-dependent binding detection of scFv antibody phage to HBsAg for 24 excellent candidates of phage scFv after the fourth screening using four gradients and 5-fold dilution, the abscissa represents dilution ratio, and the ordinate represents OD value. The results show that A41-8, A42-12 and A42-23 are better than A31-73, and A44-1 and A44-20 are equivalent to A31-73. [Diagram 5] FIG. 1 shows an overview of the mutation sites of A31-73, A42-13, A42-23 and A41-8. [Figure 6] FIG. 1 shows the HPLC results of A31-73, A42-12, A42-23 and A41-8 in Example 2, where M1D-C / S is a positive control, referring to different batches of M1D antibody, and the results show that the four antibodies are a single component. [Figure 7]1 shows the results of detection of binding to HBsAg at pH 7.4 and pH 6.0 for A31-73, A42-12, A42-23 and A41-8 in Example 3. Here, the abscissa represents the antibody concentration (Log10 ng / ml) and the ordinate represents the OD value. The results show that all four antibodies can maintain the same antigen-binding activity as the parent antibody at neutral pH, and all of them have significantly reduced antigen-binding activity under pH 6.0 conditions, with A31-73 being better than A42-12, A42-23 and A41-8. [Figure 8] Figure 8 shows the results of the therapeutic effect of A31-71, A41-8, A42-12 and parental M1D in HBV transgenic female mice of Example 3. Figure 8A: Clearance effect of HBsAg in mouse serum, the abscissa represents the number of days (d) after antibody injection, and the ordinate represents the level of HBsAg in mouse serum after clearance (log10 IU / ml). Figure 8B: Change in antibody concentration in mouse serum, the abscissa represents the number of days (d) after antibody injection, and the ordinate represents the antibody concentration (Log10 ng / ml). The results show that HBsAg levels of M1D return to baseline after about 10 days, while our modified antibody returns to baseline after about 15 days. With regard to antibody concentrations in serum, M1D had the lowest antibody concentration on day 10, whereas the three modified antibodies could still be detected on day 15, indicating that the pH-dependent modified antibodies exhibited the same ability to clear HBsAg as the parent and had a longer antigen inhibition time than the parent, i.e., their clearance effect could be exerted for a longer period of time. [Figure 9]9 shows the principle of action of scavenger antibodies. pH-dependent antigen binding activity plays a role inside cells. Therefore, unless the initial limiting factor of cell entry is broken, the pH-dependent antigen binding property will not be applied afterwards, and the benefit of modification will be greatly reduced. Scavenger antibodies obtained by further mutation of amino acids in the Fc region can enhance binding to hFcRn receptors at neutral pH or enhance binding to FcγRs receptors. As shown in FIG. 9, scavenger antibodies are located outside cells and act as "transport helpers" that can extremely extend antibody half-life by transporting antigens back and forth into cells, and can bind to antigens again, thereby improving the cell entry efficiency of antigens and greatly improving clearance efficiency. [Figure 10] Figure 1 shows the HPLC results of two molecules A31-73 and A41-8 in Example 4, where red and green represent irrelevant positive controls. The results show that all antibodies are single components. [Figure 11] Figure 1 shows the results of detection of binding to HBsAg at pH 7.4 and pH 6.0 for A31-73 V4 and A41-8 V4 in Example 4, where the abscissa represents the antibody concentration (Log10 ng / ml) and the ordinate represents the OD value. The results show that both molecules can maintain the antigen-binding activity and pH-dependent antigen-binding activity of the parent antibody at neutral pH, and the pH-dependent antigen-binding activity is slightly enhanced. [Figure 12]12A and 12B show the immunofluorescence results of A31-73 V4 and A31-73 (FIG. 12A), and A41-8 V4 and A41-8 (FIG. 12B) on MDCK cells in Example 4. Green fluorescence represents hFcRn, blue fluorescence represents nuclei, and red fluorescence represents HBsAg. The results show that the antigen fluorescence intensity in cells treated with A31-73 V4 and A41-8 V4 mutants is significantly higher than that in cells treated with A31-73 and A41-8, indicating that scavenger antibodies with V4 modification can efficiently transport more antigens into cells. It is confirmed that the V4 mutation in scavenger antibodies can enhance the binding of antibodies to hFcRn under neutral conditions. After the antigen-antibody complex enters the cells, the antigen-antibody complex dissociates under an intracellular pH of only about 6.0, and the antibody returns to the cell surface and performs the antigen-binding function again. The enhanced ability of scavenger antibodies to bind to hFcRn under neutral conditions may improve the subsequent pH-dependent antigen binding properties. [Figure 13]13A shows the therapeutic effect of two scavenger antibodies A31-73 V4 and A41-8 V4, M1D and negative control 16G12 by single injection via tail vein at a dose of 20 mg / kg in hFcRn transgenic mice with stable HBV viral titers of Example 4. Fig. 13A shows the clearance effect of HBsAg in mouse serum, the abscissa represents the number of days (d) after antibody injection, and the ordinate represents the clearance level of HBsAg in mouse serum (log10 IU / ml). Fig. 13B shows the clearance effect of HBV DNA in mouse serum, the abscissa represents the number of days (d) after antibody injection, and the ordinate represents the clearance level of HBV DNA in mouse serum (log10 IU / ml). Fig. 13C shows the change in antibody concentration in mouse serum, the abscissa represents the number of days (d) after antibody injection, and the ordinate represents the antibody concentration (Log10 ng / ml). The results show that the scavenger antibodies have the same antigen clearance ability as M1D, but have a longer inhibition time. After M1D exerts the maximum antigen clearance effect, the antigen begins to recover rapidly, and M1D begins to expire on the 14th day, and HBsAg in serum returns to the baseline level (based on the negative control 16G12). However, the two scavenger antibodies can maintain low antigen levels for a long time after exerting the maximum clearance effect, and recover slowly. In the A41-8 V4 treatment group, HBsAg recovers to the baseline in about 30 days. A31-73 V4 performed better. Even after the scheduled end of the experiment, HBsAg did not return to the baseline level, which is consistent with the detection results of antibody half-life in serum. [Figure 14] This is a protein gel result of A31-73 DY in Example 4. M1D is a positive control. The results show that all antibodies are single components. [Figure 15]1 shows the results of detecting A31-73 DY binding to HBsAg at pH 7.4 and pH 6.0 in Example 4. Here, the abscissa represents the antibody concentration (Log10 ng / ml) and the ordinate represents the OD value. The results show that A31-73 DY can maintain the antigen-binding activity and pH-dependent antigen-binding activity of the parent antibody at neutral pH, and the pH-dependent antigen-binding activity is slightly enhanced. [Figure 16] Figure 1 shows the results of immunofluorescence experiments for A31-73 DY and A31-73 on mouse primary macrophages in Example 4. Here, green fluorescence represents hFcRn, blue fluorescence represents nuclei, and red fluorescence represents HBsAg. The results show that DY modification enhances phagocytosis of antigen-antibody complexes by mouse macrophages. [Figure 17] 17 shows the therapeutic effect of A31-73 DY scavenger antibody and M1D of Example 4 after a single injection via tail vein at a dose of 5 mg / kg in HBV transgenic mice. Figure 17A: Clearance effect of HBsAg in mouse serum, the abscissa represents the number of days (d) after antibody injection, and the ordinate represents the level of HBsAg in mouse serum after clearance (log10 IU / ml). Figure 17B: Clearance effect of HBV DNA in mouse serum, the abscissa represents the number of days (d) after antibody injection, and the ordinate represents the clearance level of HBV DNA in mouse serum (log10 IU / ml). Figure 17C: Change in antibody concentration in mouse serum, the abscissa represents the number of days (d) after antibody injection, and the ordinate represents the antibody concentration (ng / ml). The results show that the scavenger antibody A31-73 DY with DY modification is more than one order of magnitude stronger than M1D in antigen clearance. A31-73 DY can not only rapidly clear HBsAg in HBV transgenic mice, but also effectively reduce HBV DNA titers in mice, which is consistent with the detection results of antibody half-life in serum.Comparing the antibody concentration in serum, the half-life of A31-73 DY is nearly 8 days longer than that of M1D, indicating that the scavenger antibody A31-73 DY has the function of binding antigens to each other, which increases the time of antigen clearance. [Figure 18] Figure 18 shows the therapeutic effect of the scavenger antibody A31-73 DY of Example 4 and the negative control 16G12 after 5 injections of the scavenger antibody at a dose of 5 mg / kg in an HBV mouse model obtained by transfection with adeno-associated virus. Figure 18A: Schematic diagram of the animal experiment, the numbers represent the days, the red arrows represent the time of blood collection, and the white arrows represent the time of administration. Figure 18B: Clearance effect of HBsAg in mouse serum, the abscissa represents the number of days (d) after antibody injection, and the ordinate represents the clearance level of HBsAg in mouse serum (log10 IU / ml). Figure 18C: Relative titer of anti-HBs in mouse serum, the abscissa represents the antibody name, and the ordinate represents the relative titer of anti-HBs (log10 OD450 / OD630). The results show that the scavenger antibody A31-73 DY overcomes the limitations of conventional antibodies, achieving low-dose, low-frequency treatment, inhibiting HBsAg titers in mice to levels below 100 IU / mL for a long period of time, and activating the humoral immune response in mice after treatment, enabling the production of anti-HBs. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0108] Sequence information Some sequence information relevant to the present invention is provided in Table 1 below.

[0109] [Table 1-1]

[0110] [Table 1-2]

[0111] [Table 1-3]

[0112] [Table 1-4] EXAMPLES

[0113] The invention will now be described with reference to the following examples, which are not intended to limit the invention but are intended to illustrate the invention.

[0114] Unless otherwise specified, the molecular biology experimental methods and immunoassay methods used in the present invention are essentially based on J. Sambrook et al., Molecular Cloning: Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989, and FM Ausubel et al., Compiled Molecular Biology Experiment Guide, 3rd edition, John Wiley & Sons, Inc., 1995, and restriction enzymes were used according to the conditions recommended by the product manufacturers. Those skilled in the art will understand that the examples are illustrative of the present invention and are not intended to limit the scope of protection claimed by the present invention.

[0115] Example 1: Phage screening of pH-dependent anti-HBsAg antibodies 1.1 Determining Mutation Sites for pH-Dependent Antibody Modification The anti-HBV humanized antibody M1D (described in detail in China Patent Application Publication No. 201810307136.5) previously developed in the laboratory was used as the parent antibody, and its variable region was modified for pH-dependent antigen binding. As shown in Figure 1, the modified M1D could maintain antigen-binding activity under neutral conditions, but its antigen-binding activity under acidic conditions was greatly reduced. The dissociated modified M1D could bind to intracellular FcRn, return to plasma, and bind to antigen again, so that one molecule of M1D after pH-dependent antigen-binding modification could repeatedly bind to and neutralize multiple molecules of antigen. Histidine could be protonated under acidic conditions, and was a key amino acid that resulted in pH-dependent antigen-binding properties. The three-dimensional structure of the variable region of M1D was simulated (the three-dimensional structure of the variable region was simulated according to the amino acid sequence of the variable region) and is shown in Figure 2. The rod-shaped structure represented the CDR region, blue represented the VK CDR, green represented the VH CDR, and red represented the surface amino acids. A total of 25 surface amino acids are found in the CDR regions, and combining this with experience gained from amino acids disclosed in the literature, it was determined that there are 24 random substitution sites for histidine.

[0116] 1.2 Construction of a phage library of pH-dependent scFv antibodies derived from M1D Using the variable regions of the light and heavy chains of the M1D antibody as templates, the 24 sites determined in the antibody variable region CDR were replaced with histidine, and the target fragment was amplified according to the primers in Table 2 to obtain a gene fragment encoding a pH-dependent scFv antibody derived from M1D. The PCR conditions were 95°C, 5 min; 95°C, 30 sec; 57°C, 30 sec; 72°C, 30 sec; 72°C, 10 min for 25 amplification cycles, and the SOE-PCR reaction conditions were 95°C, 5 min; 95°C, 30 sec; 57°C, 30 sec; 72°C, 30 sec; 72°C, 10 min for 5 amplification cycles. The amplified product was analyzed by agarose gel electrophoresis, and the amplified product was recovered / purified using a DNA purification and recovery kit (TianGen, DP214-03) to obtain gene fragments H to K encoding a pH-dependent scFv antibody derived from M1D. The structure of the scFv antibody was NH2-VH-linker-VL-COOH, and the linker sequence could be (G4S)3. Each of the gene fragments H to K was digested with SfiI and then ligated into the vector pCGMT (by Scripps, Making chemistry selectable by linking it to infectivity) at a molar ratio of 10:1 (gene fragment:vector). The ligation product was transformed into competent E. coli ER2738 by electroporation (electroporation conditions: 25 μF, 2.5 KV, 200 Ω). After the transformed E. coli was allowed to recover in SOC medium for 45 minutes, 200 μL of the bacterial solution was plated on an LB plate (containing 100 g / L ampicillin + tetracycline + 2 g / mL glucose) and incubated overnight at 37 °C. All colonies on the plate were the library in which the determined mutation sites in the variable region were randomly mutated to histidine, and this was used for subsequent screening. Monoclonal colonies were selected from the plate and sequenced to confirm the accuracy of the sequence of the recombinant vector encoding the scFv antibody. A schematic diagram of the recombinant vector encoding the scFv antibody (pCGMT-scFv) is shown in FIG. 3.

[0117] [Table 2]

[0118] 1.3 Screening of pH-dependent scFv antibodies The library obtained in the previous step was screened multiple times, and the positive monoclonal colonies obtained in the screening were cultured in 2xYT medium containing ampicillin (100g / L) and glucose (2g / mL) to reach an OD value of 0.6, and then M13KO7 was added for auxiliary superinfection. After 2 hours, 100g / L kanamycin was added, and superinfection was performed at 37°C. After 2 hours, the culture was centrifuged at 4000 rpm for 10 minutes, the supernatant was discarded, and the cell pellet was collected. The cell pellet was resuspended in medium containing ampicillin and kanamycin (100g / L) and cultured overnight at 30°C with shaking. The culture was then centrifuged at 12000 rpm for 10 minutes, and the cells and supernatant were collected and stored at 4°C for testing.

[0119] HBsAg (200ng / mL) antigen coated ELISA plate was taken, 100μL of the tested supernatant was added to each well, and incubation was performed at 37℃ for 1 hour (two wells for each supernatant). Then, ELISA plate was washed once with PBST, and 120μL of PBS pH7.4 and PBS pH6.0 were added to two wells of each supernatant, respectively, and incubated at 37℃ for 30 minutes. Five washes were performed with PBST of the corresponding pH, and 100μL of 5000-fold diluted anti-M13-HRP was added and incubated at 37℃ for 30 minutes. Then, ELISA plate was washed five times with PBST, and substrate TMB solution was added. After 15 minutes of color development, the color reaction was stopped with H2SO4, and reading was performed at OD. 450 / 620 The results of the third ELISA test are shown in Figures 4A to 4C. The results in Figures 4A to 4C show that all of the phages displaying these scFv antibodies were reactive in ELISA detection and could weakly bind to the antigen at pH 6.0. Four strains of pH-dependent phage antibodies with good effects were initially obtained and named A31-73, A42-13, A42-23 and A41-8.

[0120] Example 2: Preparation of pH-dependent anti-HBsAg antibody 2.1 Construction of recombinant vectors for eukaryotic expression In the present invention, since it is necessary to carry out a large amount of antibody recombination, it is necessary to construct a set of light and heavy chain vectors that can efficiently recombine antibodies. In the present invention, the existing eukaryotic expression vector pTT5 in the laboratory was specially modified to construct a set of light and heavy chain recombination vectors for dual plasmid co-transfection. MGWSCIILFLVATATGVHS (SEQ ID NO: 49) was used as the signal peptide of the light and heavy chains. The sequences encoding the constant regions of the light and heavy chains of human antibodies were separately ligated downstream of the signal peptide to construct a series of eukaryotic expression vectors pTT5-CH, pTT5-Cκ and pTT5-Cλ, which facilitate antibody recombination.

[0121] Using the four scFv antibodies obtained in 1.3, light and heavy chain variable region fragments were amplified with the primers in Table 3. The specific amplification reaction conditions were 95°C, 5 minutes; 95°C, 30 seconds; 57°C, 30 seconds; 72°C, 30 seconds; and 72°C, 10 minutes, with 25 amplification cycles. The amplified products were recovered from the gel.

[0122] Using Gibson assembly solution made in the laboratory, the recovered PCR products of the antibody variable region genes were ligated to the constructed eukaryotic expression vectors (the primers have sequences homologous to the vectors) to obtain recombinant vectors VH+pTT5-CH (containing the heavy chain constant region shown in SEQ ID NO: 57) and VH+pTT5-Cκ (containing the light chain constant region shown in SEQ ID NO: 58). The recombinant vectors were transformed into E. coli DH5α strain, plated on LB plates, and cultured overnight in an incubator at 37°C. Monoclonal colonies were picked from the plates and sequenced, and the sequencing results were subjected to sequence comparison using MEGA to confirm the accuracy of the genes and exclude genes with incorrect information.

[0123] [Table 3]

[0124] 2.2 Small-scale and large-scale expression of antibody genes The constructed recombinant vectors VH+pTT5-CH and VH+pTT5-Cκ were co-transfected into HEK293 cells, and the dual plasmids for small-scale expression were co-transfected into a 24-well plate at 500 μL per well. When the cell supernatant for small-scale expression had antigen activity, the transfection system was transferred to 100 mL (depending on the amount of antibody used) of FreeStyle™ 293F suspension cells (cell density was approximately 2 × 10 6 The transfected cells were cultured in shake flasks in a 32° C., 5% CO2 incubator and supernatants were harvested after 7 days of expression.

[0125] 2.3 Antibody purification The cell expression supernatant was collected and purified using a protein A column according to the manufacturer's instructions. The specific steps were as follows: the collected cell culture supernatant was centrifuged at 8000 rpm for 10 min, the supernatant was retained, and the pH value was adjusted to 8.4 with dry powder Na2HPO4, and then filtered through a filter membrane with a pore size of 0.22 μm. 10 mL of Sepharose 4B medium bound with protein A was loaded into the column and connected to an AKTA Explorer 100 system, pump A was connected to 0.2 M disodium hydrogen phosphate solution, and pump B was connected to 0.2 M citric acid solution. The detection wavelength was UV280 nm, the flow rate was 5 mL / min, and the sample injection ratio of pump A / B was adjusted. The column was first washed with 100% B (pH 2.3) to remove protein impurities, and the pH was balanced with 10% B (pH 8.0), and the sample was loaded after the signal at the detection wavelength was stable and returned to zero. After the flow-through peak, the signal at the detection wavelength dropped to zero and was balanced using 10% B until it stabilized, and elution was performed using 70% B (pH 4.0) to collect the elution peak. The elution peak sample was dialyzed into PBS buffer and subjected to concentration assay and SDS-PAGE and HPLC analysis to determine the purity of the IgG antibody. The HPLC results of A31-73, A42-12, A42-23 and A41-8 are shown in Figure 6. The four antibodies are single components.

[0126] Example 3: Characterization and functional evaluation of pH-dependent anti-HBsAg antibodies Four phage antibody strains having pH-dependent binding properties to HBsAg obtained by preliminary screening according to the method of Example 1 were named A31-73, A42-13, A42-23 and A41-8, respectively. Furthermore, the four phage antibody strains were subjected to eukaryotic expression and purification according to the method of Example 2. The VH and VL amino acid sequences of the four antibodies are shown in the table below. In addition, the CDR sequences of the four antibodies were determined, and the amino acid sequences of the CDRs of the heavy chain variable region and the light chain variable region are shown in Table 5. The mutation sites that conferred pH-dependent antigen-binding properties to HBsAg to A31-73, A42-13, A42-23 and A41-8 are summarized in Table 5.

[0127] [Table 4]

[0128] [Table 5]

[0129] 3.1 Determination of pH-dependent anti-HBsAg antibody antigen-binding activity at different pH The inventors tested the pH-dependent antigen binding ability of A31-73, A42-12, A42-23 and A41-8 to HBsAg by ELISA. First, the concentration of the purified antibody was determined using a BCA protein quantification kit, and the antibody concentration was standardized to 1111.11ng / mL by dilution. Then, the antibody concentration was diluted 3-fold using 20% ​​NBS, and a total of 8 concentrations were obtained by gradient dilution. Then, the diluted antibody was added to a commercial HBsAg plate (purchased from Beijing Wantai) and incubated at 37°C for 1 hour (2 wells per supernatant). Then, the ELISA plate was washed once with PBST and spun dry. Then, 120μL of PBS at pH 7.4 and pH 6.0 was added to two wells of each supernatant and incubated at 37°C for 30 minutes. The plate was washed 5 times with PBST of the corresponding pH and spun dry. Then, GAH-HRP-labeled secondary antibody was added and incubated for 30 min, the plate was washed 5 times with PBST and spun dry, and substrate TMB solution was added. After 15 min of color development, the color reaction was stopped with H2SO4, and the reading was measured at OD450 / 630.

[0130] The results are shown in Figure 7. At pH 7.4, A31-73, A42-12, A42-23 and A41-8 all had antigen-binding activity equivalent to that of M1D, but at pH 6.0, their antigen-binding activity was significantly reduced. The EC50 results are summarized in Table 6.

[0131] [Table 6]

[0132] 3.2 Determining the therapeutic efficacy of pH-dependent anti-HBsAg antibodies in animal models HBV transgenic mice were used to evaluate the ability of the above-mentioned pH-dependent anti-HBsAg antibody to clear HBV virus in animals. The pH-dependent anti-HBsAg antibody and parental antibody M1D were administered to HBV transgenic mice (provided by Professor Chen Peizhe of National Taiwan University) by tail vein injection at a dose of 10 mg / kg, with 4 or 5 HBV transgenic mice per group. Subsequently, blood samples were collected from the retro-orbital venous plexus of the mice to detect the changes in HBsAg and antibody levels in the mice serum.

[0133] 3.2.1 Quantitative detection of HBsAg (1) Preparation of reaction plate: Mouse monoclonal antibody HBs-45E9 was diluted to 2 μg / mL in 20 mM PB buffer (Na2HPO4 / NaH2PO4 buffer, pH 7.4), and 100 μL of coating solution was added to each well of the chemiluminescence plate for coating at 2°C-8°C for 16-24 hours, followed by another 2 hours at 37°C. The plate was washed once with PBST washing solution and spun dry. After washing, 200 μL of blocking solution was added to each well for blocking at 37°C for 2 hours. The blocking solution was then discarded, and the plate was dried in a drying room and stored at 2°C-8°C for later use. (2) Sample dilution: The collected mouse serum was diluted with PBS solution containing 20% ​​NBS (newborn bovine serum) to form two gradients of 1:30 and 1:150 for subsequent quantitative detection. (3) Denaturation of the sample: 15 μL of the diluted serum sample was thoroughly mixed with 7.5 μL of denaturation buffer (15% SDS dissolved in 20 mM PB7.4) and reacted for 1 hour at 37° C. Then, 90 μL of stop buffer (4% CHAPS dissolved in 20 mM PB7.4) was added and thoroughly mixed. (4) Sample reaction: 100 μL of the above-mentioned denatured serum sample was added to the reaction plate and reacted for 1 hour at 37° C. Then, the reaction plate was washed five times with PBST and spun dry. (5) Enzyme labeling reaction: HBs-A6A7-HRP reaction solution was added to the chemiluminescence plate at 100 μL / well and reacted for 1 hour at 37° C. The plate was then washed five times with PBST and spun dry. (6) Luminescence reaction and measurement: The luminescence solution was added to the chemiluminescence plate (100 μL / well), and light intensity detection was performed. (7) Calculation of HBsAg concentration in mouse serum samples: A parallel experiment was performed using a standard, and a standard curve was drawn based on the measurement results of the standard. The light intensity measurements of the mouse serum samples were then substituted into the standard curve to calculate the concentration of HBsAg in the serum samples to be tested.

[0134] 3.2.2 Quantitative detection of antibodies in serum (1) Sample dilution: serum samples were diluted in 20% NBS in three gradients of 1000-fold, 10000-fold, and 100000-fold. The corresponding control antibody was diluted to 20 ng / mL in 20% NBS in the first well, and then diluted 3-fold in six gradients. (3) Addition of samples: 100 μL / well of the samples diluted in the previous step and the corresponding antibody dilutions were added to a commercial HBsAb plate (purchased from Beijing Wantai) and incubated at 37° C. for 1 hour. (4) Washing: the plate was washed 5 times with 300 μL / well of PBST using a plate washer and spun dry; (5) Addition of enzyme-labeled secondary antibody: add 100 μL / well of GAH-HRP-labeled secondary antibody dilution and incubate at 37° C. for 30 minutes; (6) Washing: The plate was washed 5 times with 300 μL / well of PBST using a plate washer and spun dry. (7) Color development: 100 μL / well of color development solution, 37° C., 10 to 15 minutes; (8) Stop and read: 50 μL / well of stop solution was added and the readings were measured at OD450 / 630 by a microplate reader within 10 minutes. (9) Calculation of antibody concentration in mouse serum samples: A standard curve was drawn based on the measurement results of the corresponding standard antibody. The light intensity measurements of the mouse serum samples were then substituted into the standard curve to calculate the antibody concentration in the serum samples to be tested.

[0135] The detection results of HBsAg and antibody levels in the serum of mice after antibody treatment are shown in Figure 8A and Figure 8B. The results showed that the HBsAg level of the parent antibody M1D returned to baseline after about 10 days, while the HBsAg level of the pH-dependent antibodies returned to baseline after about 15 days. Comparing the antibody concentrations in serum, M1D showed the lowest antibody concentration on day 10, while the three pH-dependent antibodies could still be detected on day 15, indicating that the pH-dependent antibodies have a longer antigen inhibition time than the parent antibodies while maintaining the same ability to clear HBsAg as the parent antibodies, i.e., the clearance effect of the pH-dependent antibodies can be exerted for a longer period of time. The results of HBsAg clearance by A31-73, A42-12 and A41-8 are shown in Figure 8A, and the results of the serum concentrations of A31-73, A42-12 and A41-8 are shown in Figure 8B. The results of the therapeutic effects in animals indicated that A31-73, A42-12 and A41-8 have the potential to treat HBV infection or diseases associated with HBV infection (eg, hepatitis B).

[0136] Example 4: Construction and functional evaluation of scavenger antibodies A pH-dependent antibody needs to enter cells to exert its pH-dependent antigen-binding activity. Therefore, unless the initial limiting factor of cell entry is broken, there is no chance for the subsequent pH-dependent antigen-binding property to "work". Therefore, in this example, a scavenger antibody that can enhance binding to the hFcRn receptor or enhance binding to the FcγRs receptor at neutral pH was obtained by further mutation of amino acids in the Fc region. As shown in FIG. 9, the scavenger antibody is located outside the cell and plays the role of a "transport helper" that extremely extends the antibody half-life by transporting the antigen back and forth into the cell, and can bind to the antigen again, thereby improving the efficiency of the antigen's cell entry and greatly improving the clearance efficiency.

[0137] 4.1 Scavenger antibodies capable of binding to hFcRn 4.1.1 Construction, Expression and Purification of Scavenger Antibodies Capable of Binding to hFcRn A31-73 and A41-8, which have the best performance in HBV transgenic mice in Example 3, were subjected to V4 (M252Y, N286E, N434Y) mutation in the Fc region to enhance the affinity to hFcRn under neutral conditions (this work was entrusted to General Biology; order number: G120460). Two scavenger antibodies A31-73 V4 and A41-8 V4 were obtained, and the heavy chain constant region after mutation is shown in SEQ ID NO: 47. The above two antibodies were subjected to large-scale eukaryotic expression and purification, and the specific operation steps are shown in Examples 2.2 and 2.3. The HPLC results of A31-73 V4 and A41-8 V4 are shown in Figure 10, and the results show that the antibodies are single components.

[0138] 4.1.2 In vitro activity detection of scavenger antibodies capable of binding to hFcRn 4.1.2.1 Determination of antigen binding activity of scavenger antibodies capable of binding to hFcRn at different pH The antigen-binding activity of A31-73 V4 and A41-8 V4 at pH 7.4 and pH 6.0 was detected, respectively, and the specific operation steps were shown in Example 3.1. The results were shown in Figure 11. The results showed that both A31-73 V4 and A41-8 V4 could maintain the same antigen-binding activity as their parents at neutral pH, and the antigen-binding activity at acidic pH was further weakened, indicating that the pH-dependent antigen-binding activity of A31-73 V4 and A41-8 V4 was enhanced to a certain extent.

[0139] 4.1.2.2 Functional validation at the cellular level of scavenger antibodies capable of binding to hFcRn 4.1.2.2.1 Labeling of HBsAg with 488 fluorescence Take the labeling of 1 mg of HBsAg as an example, and the whole process was protected from light. (1) 1 mL of 1 mg / mL HBsAg was dialyzed against borate buffer (pH 8.5, 500 mL) at 4°C for 4 hours; (2) The molar ratio of HBsAg to 488 label was 1:5, and it was calculated that 0.1988 mg of 488 fluoro was required; (3) A 10 mg / mL solution of 488 fluorescent was prepared in DMF and mixed well; (4) 19.88 μL of 488 Fluorescence was added to 1 mL of dialyzed HBsAg, mixed well, and incubated at room temperature for 1 h; (5) The incubation mixture was dialyzed against PBS overnight at 4°C.

[0140] 4.1.2.2.2 Immunofluorescence experiments based on MDCK cells (All steps using fluorescently labeled samples were performed in a dark environment.) (1) Cell plating: 2 × 10 5 Cells at a density of 1000 cells / mL were cultured overnight at 250 μL / well in 24-well glass-bottom culture plates for cell imaging; (2) Corresponding fluorescently labeled antibodies and antigens were diluted in serum-free medium: 800 ng / mL for antigens and 2 μg / mL for antibodies; (3) 125 μL each of the antigen and antibody were uniformly mixed and then allowed to stand in a CO2 incubator at 37°C for 1 hour; (4) The cell supernatant in the cell imaging culture plate was discarded, and the antigen-antibody complex was added, shaken uniformly, and allowed to stand in a CO2 incubator at 37°C for 2 hours; (5) The supernatant was discarded, and the cell surface was "washed" 3 to 5 times with 1 mL of sterile PBS pre-incubated at 37°C and removed by pipetting; (6) 1 mL of 10% paraformaldehyde was added and the sample was left in a CO2 incubator at 37°C protected from light for 0.5 hours; (7) The paraformaldehyde was discarded, and the cell surface was "washed" 3 to 5 times with 1 mL of sterile PBS that had been pre-incubated at 37°C, and then removed by pipetting; (8) 0.5 mL of DAPI (diluted 1000-fold with sterile PBS) was added, and the mixture was left in a CO2 incubator at 37°C protected from light for 15 minutes; (9) Discard the DAPI dilution, and "wash" the cell surface 3 to 5 times with 1 mL of sterile PBS that had been pre-incubated at 37°C, remove by pipetting, add 0.5 mL of PBS, and place in a high-content imager for imaging.

[0141] The experimental results are shown in Figures 12A and 12B. The results showed that the antigen fluorescence intensity in cells treated with A31-73 V4 and A41-8 V4 was significantly higher than that in cells treated with A31-73 and A41-8, indicating that the above scavenger antibody can efficiently transport more antigens into cells. This result confirmed that the V4 mutation in the scavenger antibody can enhance the binding of the antibody to hFcRn under neutral conditions. After the antigen-antibody complex entered the cell, the intracellular pH was only about 6.0, and the antibody dissociated from the antigen-antibody complex and returned to the cell surface to perform the antigen-binding function again. The enhanced ability of the scavenger antibody to bind to hFcRn under neutral conditions may open the "convenience door" of subsequent pH-dependent antigen-binding properties.

[0142] 4.1.3 Determining the therapeutic efficacy of scavenger antibodies capable of binding to hFcRn in animal models The V4 modification was directed at the hFcRn receptor. The receptor of HBV transgenic mice was mFcRn, which could not be used to evaluate the effect of modification. Therefore, a model of hFcRn transgenic mice infected with rAAV-HBV adr was adopted. Six- to eight-week-old hFcRn transgenic mice (purchased from Biosaitu) were subjected to a single injection of an appropriate dose of rAAV-HBV adr (purchased from Beijing Wujiahe Molecular Medicine Institute Co., Ltd.) via the tail vein. The HBV virus titer in the mice was continuously monitored for 4 weeks. After the virus titer was stabilized, the hFcRn transgenic mice (four mice per group) with stable HBV virus titer were injected with two scavenger antibodies M1D and negative control 16G12 via the tail vein at a single dose of 20 mg / kg each, and supported by intraperitoneal injection of anti-CD4 antibody to suppress humoral immune response. Serum HBsAg, antibody and HBV DNA concentrations were then measured, and the in vivo antigen clearance rate and antibody half-life of the scavenger antibodies were analyzed.

[0143] 4.1.3.1 Quantitative detection of HBsAg The specific steps are shown in Example 3.2.1, and the detection results of A31-73 V4 and A41-8 V4 are shown in Figure 13A.

[0144] 4.1.3.2 Quantitative detection of antibodies in serum The specific steps are shown in Example 3.2.2, and the detection results of A31-73 V4 and A41-8 V4 are shown in Figure 13B.

[0145] 4.1.3.3 Quantitative detection of HBV DNA Quantitative detection of HBV DNA was performed according to the instructions of the HBV DNA real-time fluorescent quantitative detection kit (the kit was purchased from Beijing Jinmaige Biotechnology Co., Ltd.).

[0146] In this example, the viral clearance capabilities of A31-73 V4, A41-8 V4 and the reference antibody M1D in animals were determined, and the experimental results are shown in Figure 13C.

[0147] The results in Figures 13A to 13C show that the scavenger antibodies A31-73 V4 and A41-8 V4 have antigen clearance capabilities comparable to M1D, but have longer inhibition times. After M1D exerted its maximum antigen clearance effect, antigen recovery began rapidly, and M1D began to expire on day 14, and HBsAg in serum returned to baseline levels (based on the negative control 16G12). However, the two scavenger antibodies were able to maintain lower antigen levels for a long period of time and recover slowly after exerting their maximum clearance effect. In the A41-8 V4 treatment group, HBsAg recovered to baseline in about 30 days. In the A31-73 V4 treatment group, HBsAg did not return to baseline levels even after the scheduled end of the experiment. These were consistent with the detection results of antibody half-life in serum. Such technical effects are noteworthy and unexpected.

[0148] 4.2 Scavenger antibodies capable of binding to mFcγRII 4.2.1 Construction, Expression and Purification of Scavenger Antibodies Capable of Binding to mFcγRII A31-73 and A41-8, which have the best performance in the HBV transgenic mice of Example 3, were subjected to DY (K326D, L328Y) mutation on the Fc region (this work was entrusted to General Biology; order number: G120460), to obtain A31-73 DY and A41-8 DY, respectively, whose heavy chain constant regions after mutation are shown in SEQ ID NO: 48. The antibodies were subjected to large-scale eukaryotic expression and purification, and the specific operation steps are shown in Examples 2.2 and 2.3. The protein gel results of A31-73 DY are shown in Figure 14. The results show that the antibody is a single component.

[0149] 4.2.2 In vitro activity detection of scavenger antibodies capable of binding to mFcγRII 4.2.2.1 Determination of antigen binding activity of scavenger antibodies capable of binding to mFcγRII at different pH The antigen-binding activity of A31-73 DY was detected at pH 7.4 and pH 6.0, respectively. The specific procedure is described in Example 3.1. The results are shown in Figure 15. A31-73 DY was able to maintain the same antigen-binding activity and pH-dependent antigen-binding activity as the parent antibody at neutral pH, and the antigen-binding activity at acidic pH was further weakened, indicating that the pH-dependent antigen-binding activity of A31-73 DY was enhanced to some extent.

[0150] 4.2.2.2 Functional validation at the cellular level of scavenger antibodies capable of binding to mFcγRII 4.2.2.2.1 Labeling of HBsAg with 488 fluorescence The specific steps are shown in 4.1.2.2.1.

[0151] 4.2.2.2.2 Immunofluorescence experiments based on primary mouse macrophages (1) Four days before the experiment, 1.5 mL of 3% sodium thioglycolate solution was injected intraperitoneally but not intraintestinally into each mouse; (2) Two mice were sacrificed and immersed in 75% alcohol for 3 min; (3) The mouse was fixed horizontally on a foam board, and the abdomen was exposed. The abdominal skin was cut with tissue scissors, the peritoneum was disinfected, and the abdominal cavity was exposed by incision. The skin at the abdominal incision was pulled and fixed with two hooked scissors held in the left hand, and 1640 culture medium was pipetted with a Pasteur pipette held in the right hand, and peritoneal washing was performed twice in total at 4 mL per time. To make the washing more complete and thorough, the peritoneal cavity was gently and thoroughly stirred with a pipette. After thoroughly stirring for about 2 minutes and leaving it to stand for about 5 minutes to thoroughly isolate the macrophages, the washing solution was pipetted and transferred to a centrifuge tube; (4) 4°C, 1100g, 5 min; (5) The supernatant was carefully discarded, the cells were washed twice with 1640 medium, centrifuged at 1100g for 5 min at 4°C, the supernatant was discarded, and the cells were resuspended in RPM1640; (6) After counting the cells, 6 The cells were adjusted to have a density of 1000 cells / mL and cultured at 250 μL / well on a 24-well glass-bottom cell imaging culture plate, the medium was replaced after 2 hours, washed once with RPM1640, and non-adherent cells were discarded, followed by incubation overnight in a CO2 incubator at 37°C; (7) The corresponding fluorescently labeled antibodies and antigens were diluted in serum-free medium to 800 ng / mL for antigens and 20 μg / mL for antibodies; (8) 125 μL each of the antigen and antibody were uniformly mixed and then allowed to stand in a CO2 incubator at 37°C for 1 hour; (9) The cell supernatant in the cell imaging culture plate was discarded, and the antigen-antibody complex was added, shaken uniformly, and allowed to stand in a CO2 incubator at 37°C for 2 hours; (10) The supernatant was discarded, and the cell surface was "washed" 3 to 5 times with 1 mL of sterile PBS pre-incubated at 37°C and removed by pipetting; (11) Dio was diluted 2,000-fold and added to the cells in an amount sufficient to cover them, and the cells were incubated at room temperature for 20 minutes; (12) The supernatant was discarded, and the cell surface was “washed” 3 to 5 times with 1 mL of sterile PBS pre-incubated at 37°C and removed by pipetting; (13) Live cell nuclear dye (2 drops per 1 mL volume) was added, the cells were left at room temperature for 20 min, and then placed in a high content imager for imaging.

[0152] The experimental results are shown in Figure 16. The results showed that phagocytosis of antigen-antibody complexes by mouse macrophages was enhanced by DY modification, resulting in greater antigen degradation.

[0153] 4.2.3 Determining the therapeutic efficacy of scavenger antibodies capable of binding to mFcγRII in animal models 4.2.3.1 Evaluation of the therapeutic efficacy of scavenger antibodies in transgenic mice HBV transgenic mice aged 6 to 8 weeks were selected and injected with A31-73 DY scavenger antibody and M1D at a single dose of 5 mg / kg via the tail vein (4 mice per group). The in vivo antigen clearance rate and antibody half-life of the scavenger antibody were analyzed by detecting the concentrations of HBsAg, antibody and HBV DNA in the serum.

[0154] 4.2.3.1.1 Quantitative detection of HBsAg The specific steps are shown in Example 3.2.1, and the detection results of A31-73 DY are shown in Figure 17A.

[0155] 4.2.3.1.2 Quantitative detection of HBV DNA Quantitative detection of HBV DNA was performed according to the instructions of the HBV DNA real-time fluorescent quantitative detection kit (the kit was purchased from Beijing Jinmaige Biotechnology Co., Ltd.).

[0156] In this example, the viral clearance capabilities of A31-73 DY and the reference antibody M1D in animals were determined, and the experimental results are shown in Figure 17B.

[0157] 4.2.3.1.3 Quantitative detection of antibodies in serum The specific steps are shown in Example 3.2.2, and the detection results of A31-73 DY are shown in Figure 17C.

[0158] The results of Figures 17A to 17C show that the antigen clearance ability of the scavenger antibody A31-73 DY with DY modification is more than one order of magnitude stronger than that of M1D. A31-73 DY can not only rapidly remove HBsAg in HBV transgenic mice (Figure 17A), but also effectively reduce the HBV DNA titer in mice (Figure 17B), which was consistent with the detection results of antibody half-life in serum (Figure 17C). Comparing the antibody concentration in serum, the half-life of A31-73 DY was nearly 12 days longer than that of M1D, indicating that the scavenger antibody A31-73 DY has the function of binding antigens to each other, thereby increasing the time of antigen clearance.

[0159] 4.2.3.2 Evaluation of the therapeutic efficacy of scavenger antibodies in an adeno-associated virus-transfected HBV mouse model As shown in FIG. 18A, 4- to 6-week-old C57 mice were treated with 1×10 11 rAAV8-1.3HBV adr was injected into the mice to establish an HBV mouse model obtained by transfection of adeno-associated virus (day -28), and the mouse virus titer was continuously monitored. After the virus titer was stabilized, the baseline HBsAg level in the mice was detected and the mice were divided into groups (day -1). The scavenger antibody A31-73 DY (abbreviated as 73 DY) and the negative control 16G12 were injected five times at a dose of 5 mg / kg. Two weeks after the fifth treatment, all the mice were sacrificed, and the mouse serum was collected and the serum HBsAg and anti-HBs levels were analyzed.

[0160] 4.2.3.2.1 Quantitative detection of HBsAg The specific steps are shown in Example 3.2.1, and the detection results of A31-73 DY are shown in Figure 18B.

[0161] 4.2.3.2.2 Qualitative detection of anti-HBs (1) Sample dilution: serum samples were diluted with 20% NBS in five gradients: 100-fold, 500-fold, 2500-fold, 12500-fold, and 62500-fold; (3) Addition of samples: 100 μL / well of the samples diluted in the previous step and the corresponding antibody dilutions were added to a commercial HBsAb plate (purchased from Beijing Wantai) and incubated at 37° C. for 1 hour. (4) Washing: the plate was washed 5 times with 300 μL / well of PBST using a plate washer and spun dry; (5) Addition of enzyme-labeled secondary antibody: add 100 μL / well of GAM-HRP-labeled secondary antibody dilution and incubate at 37° C. for 30 minutes; (6) Washing: the plate was washed 5 times with 300 μL / well of PBST by plate washer and spun dry; (7) Color development: 100 μL / well of color development solution, 37° C., 10 to 15 minutes; (8) Stop and read: 50 μL / well of stop solution was added and the readings were measured at OD450 / 630 by a microplate reader within 10 minutes. (9) Calculation of anti-HBs concentration in mouse serum samples: Multiply the reading between 0.1 and 1 by the dilution factor and calculate the logarithm (log 10 ) was taken.

[0162] The results of detecting anti-HBs levels in mouse serum after antibody treatment are shown in FIG. 18C.

[0163] The results in Figure 18B show that scavenger antibody A31-73 DY can control HBsAg levels to less than 100 IU / ml for a long time in the HBV mouse model obtained by adeno-associated virus at a dose of 5 mg / kg and an administration frequency of 15 days / injection. The results in Figure 18C show the anti-HBs levels in mice on days 0, 7, 37, 52, 67 and 82, and show that mice treated with A31-73 DY antibody had higher anti-HBs levels, and 3 out of 4 mice produced obvious anti-HBs (only mice that continued treatment until the end were counted), indicating that the production of anti-HBs may be associated with the continuous inhibition of HBsAg. This shows that scavenger antibody A31-73 DY breaks through the limitations of conventional antibodies, achieving treatment at a low dose and low frequency, and more importantly, it can activate the humoral immune response in mice after long-term treatment, allowing the production of anti-HBs.

[0164] Example 5: Affinity determination of M1D, A31-73 and A41-8 HBsAg was dissolved in sodium acetate (pH 4.5) at 5 μg / mL, and the chip coating program was run on the Biacore 3000 instrument to coat HBsAg on the CM5 chip. The coating amount of HBsAg was 2400 RU. Seven concentrations of samples were prepared by diluting the analyte 2-fold from 100 nM. The affinity determination program was run on the Biacore 3000 instrument, with the flow rate set to 50 μl / min, the binding time set to 90 s, the dissociation time set to 600 s, the temperature of the sample chamber set to 10°C, the regeneration solution was 50 mM NaOH, the regeneration flow rate set to 50 μL / min, and the regeneration time set to 60 s. The results are summarized in Table 7.

[0165] [Table 7]

[0166] Although the specific embodiments of the present invention have been described in detail, it is understood by those skilled in the art that, according to all the teachings disclosed, various modifications and changes can be made to the details, and these modifications are within the protection scope of the present invention. The full scope of the present invention is given by the appended claims and any equivalents thereof. This specification discloses the following inventions. [1] An antibody or antigen-binding fragment thereof capable of specifically binding to HBsAg, which binds to HBsAg with higher affinity at neutral pH than at acidic pH, (a) a heavy chain variable region (VH) comprising the following three CDRs: (i)GGSIX 1 X 2 NFW (SEQ ID NO:50) (wherein X 1 is selected from T or H, and X 2 is selected from S or H, (ii) X 3 GX 4 X 5 X 6 X 7 T (SEQ ID NO:51) (wherein X 3 is selected from S or H, and X 4 is selected from P, S or Y; X 5 is selected from G or D; X 6 is selected from T or H, and X 7 is selected from Y or H, and (iii)ARSHX 8 YGX 9 X 10 DYAFDF (SEQ ID NO:52) (wherein 8 is selected from D or H, and X 9 is selected from S or H, and X 10 is selected from H or N, and / or (b) a light chain variable region (VL) comprising the following three CDRs: (iv) QDIX 11 X 12 S (SEQ ID NO:53) (wherein X 11 is selected from S or H, and X 12 is selected from S, Y or H, (v) an LCDR2 having the sequence of YAN (SEQ ID NO: 12); and (vi) QQYHX 13 LPLT (SEQ ID NO:54) (wherein 13 is selected from S or Y, An antibody or antigen-binding fragment thereof comprising: [2] (a) a heavy chain variable region (VH) comprising the following three CDRs: (i) HCDR1 consisting of a sequence selected from SEQ ID NOs: 8, 14, 17, and 20; (ii) HCDR2 consisting of a sequence selected from SEQ ID NOs: 9, 15, 21, and 18; and (iii) HCDR3 consisting of a sequence selected from SEQ ID NOs: 10, 16, and 22; and / or (b) a light chain variable region (VL) comprising the following three CDRs: (iv) LCDR1 consisting of a sequence selected from SEQ ID NOs: 11, 19, and 23; (v) an LCDR2 consisting of the sequence shown in SEQ ID NO: 12, and (vi) LCDR3 consisting of the sequence shown in SEQ ID NO: 13; The antibody or antigen-binding fragment thereof described in [1]. [3] (1) VH comprising the following three CDRs: HCDR1 as shown in SEQ ID NO: 8, HCDR2 as shown in SEQ ID NO: 9, and HCDR3 as shown in SEQ ID NO: 10; and VL comprising the following three CDRs: LCDR1 as shown in SEQ ID NO: 11, LCDR2 as shown in SEQ ID NO: 12, and LCDR3 as shown in SEQ ID NO: 13. (2) VH comprising the following three CDRs: HCDR1 as shown in SEQ ID NO: 14, HCDR2 as shown in SEQ ID NO: 15, and HCDR3 as shown in SEQ ID NO: 16; and VL comprising the following three CDRs: LCDR1 as shown in SEQ ID NO: 11, LCDR2 as shown in SEQ ID NO: 12, and LCDR3 as shown in SEQ ID NO: 13. (3) VH comprising the following three CDRs: HCDR1 as shown in SEQ ID NO: 20, HCDR2 as shown in SEQ ID NO: 21, and HCDR3 as shown in SEQ ID NO: 22, and VL comprising the following three CDRs: LCDR1 as shown in SEQ ID NO: 23, LCDR2 as shown in SEQ ID NO: 12, and LCDR3 as shown in SEQ ID NO: 13, or (4) VH comprising the following three CDRs: HCDR1 as shown in SEQ ID NO: 17, HCDR2 as shown in SEQ ID NO: 18, HCDR3 as shown in SEQ ID NO: 10, and VL comprising the following three CDRs: LCDR1 as shown in SEQ ID NO: 19, LCDR2 as shown in SEQ ID NO: 12, LCDR3 as shown in SEQ ID NO: 13, The antibody or antigen-binding fragment thereof according to [1] or [2], [4] the antibody or antigen-binding fragment thereof further comprises a human immunoglobulin framework region (e.g., a framework region contained in an amino acid sequence encoded by a human germline antibody gene), the framework region optionally comprising one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) back mutations from human residues to murine residues; Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain framework region comprised in an amino acid sequence encoded by a human heavy chain germline gene, and / or a light chain framework region comprised in an amino acid sequence encoded by a human light chain germline gene, Preferably, the antibody or antigen-binding fragment thereof is IGHV4-4 * The heavy chain framework regions contained in the amino acid sequence encoded by IGKV1-39 * 01, wherein the heavy chain framework region and / or the light chain framework region optionally contain one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) backmutations from human residues to murine residues; Preferably, the VH of the antibody or antigen-binding fragment thereof comprises a VH FR1 as set forth in SEQ ID NO: 24, a VH FR2 as set forth in SEQ ID NO: 25, a VH FR3 as set forth in SEQ ID NO: 26 and a VH FR4 as set forth in SEQ ID NO: 27; Preferably, the VL of the antibody or antigen-binding fragment thereof comprises a VL FR1 shown in SEQ ID NO: 28, a VL FR2 shown in SEQ ID NO: 29, a VL FR3 shown in SEQ ID NO: 30, and a VL FR4 shown in SEQ ID NO: 31. [5] the antibody or antigen-binding fragment thereof comprising: (a) a heavy chain variable region (VH) comprising an amino acid sequence selected from the following: (i) a sequence as set forth in any one of SEQ ID NOs: 1, 3, 4 and 6; (ii) a sequence having one or several amino acid substitutions, deletions or additions (e.g., one, two, three, four or five amino acid substitutions, deletions or additions) compared to the sequence shown in any one of SEQ ID NOs: 1, 3, 4, 6; or (iii) a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to any one of SEQ ID NOs: 1, 3, 4, 6; and, (b) a light chain variable region (VL) comprising an amino acid sequence selected from the following: (iv) a sequence as set forth in any one of SEQ ID NOs: 2, 5, and 7; (v) a sequence having one or several amino acid substitutions, deletions or additions (e.g., one, two, three, four or five amino acid substitutions, deletions or additions) compared to the sequence shown in any one of SEQ ID NOs: 2, 5, 7; or (vi) a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to a sequence set forth in any one of SEQ ID NOs: 2, 5, and 7; and preferably, the substitution described in (ii) or (v) is a conservative substitution. [6] (1) a VH having a sequence shown in SEQ ID NO: 1 and a VL having a sequence shown in SEQ ID NO: 2; (2) VH having the sequence shown in SEQ ID NO: 3 and VL having the sequence shown in SEQ ID NO: 2; (3) VH having the sequence shown in SEQ ID NO: 4 and VL having the sequence shown in SEQ ID NO: 5, or (4) VH having the sequence shown in SEQ ID NO: 6 and VL having the sequence shown in SEQ ID NO: 7; The antibody or antigen-binding fragment thereof according to any one of [1] to [5], [7] the antibody or antigen-binding fragment thereof further comprises a constant region derived from a human immunoglobulin; Preferably, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain constant region derived from a human immunoglobulin (e.g., IgG1, IgG2, IgG3 or IgG4) and the light chain of the antibody or antigen-binding fragment thereof comprises a light chain constant region derived from a human immunoglobulin (e.g., κ or λ); Preferably, the antibody or antigen-binding fragment thereof according to any one of [1] to [6] contains a light chain constant region (CL) shown in SEQ ID NO: 58. [8] the antibody or antigen-binding fragment thereof comprises a variant of a human IgG1 heavy chain constant region, the variant having the following substitutions compared to the wild-type sequence from which it is derived: (i) M252Y, N286E, N434Y, or (ii) K326D, L328Y, wherein the above-mentioned amino acid positions are according to the Kabat numbering system; Preferably, the antibody or antigen-binding fragment thereof according to any one of [1] to [7] comprises a heavy chain constant region (CH) shown in SEQ ID NO: 47 or 48. [9] The antibody or antigen-binding fragment thereof according to any one of [1] to [7], which contains a heavy chain constant region (CH) shown in SEQ ID NO: 57.

[10] (1) a heavy chain comprising a VH set forth in SEQ ID NO: 1 and a CH set forth in SEQ ID NO: 57, and a light chain comprising a VL set forth in SEQ ID NO: 2 and a CL set forth in SEQ ID NO: 58; (2) a heavy chain comprising a VH set forth in SEQ ID NO: 1 and a CH set forth in SEQ ID NO: 47, and a light chain comprising a VL set forth in SEQ ID NO: 2 and a CL set forth in SEQ ID NO: 58; (3) a heavy chain comprising VH set forth in SEQ ID NO: 1 and CH set forth in SEQ ID NO: 48, and a light chain comprising VL set forth in SEQ ID NO: 2 and CL set forth in SEQ ID NO: 58; (4) a heavy chain comprising VH set forth in SEQ ID NO: 3 and CH set forth in SEQ ID NO: 57, and a light chain comprising VL set forth in SEQ ID NO: 2 and CL set forth in SEQ ID NO: 58; (5) a heavy chain comprising a VH set forth in SEQ ID NO: 3 and a CH set forth in SEQ ID NO: 47, and a light chain comprising a VL set forth in SEQ ID NO: 2 and a CL set forth in SEQ ID NO: 58; (6) A heavy chain comprising a VH set forth in SEQ ID NO: 3 and a CH set forth in SEQ ID NO: 48, and a light chain comprising a VL set forth in SEQ ID NO: 2 and a CL set forth in SEQ ID NO: 58; (7) A heavy chain comprising VH set forth in SEQ ID NO: 4 and CH set forth in SEQ ID NO: 57, and a light chain comprising VL set forth in SEQ ID NO: 5 and CL set forth in SEQ ID NO: 58; (8) A heavy chain comprising a VH represented by SEQ ID NO: 4 and a CH represented by SEQ ID NO: 47, and a light chain comprising a VL represented by SEQ ID NO: 5 and a CL represented by SEQ ID NO: 58; (9) A heavy chain comprising a VH represented by SEQ ID NO: 4 and a CH represented by SEQ ID NO: 48, and a light chain comprising a VL represented by SEQ ID NO: 5 and a CL represented by SEQ ID NO: 58; (10) A heavy chain comprising VH set forth in SEQ ID NO: 6 and CH set forth in SEQ ID NO: 57, and a light chain comprising VL set forth in SEQ ID NO: 7 and CL set forth in SEQ ID NO: 58; (11) A heavy chain comprising VH set forth in SEQ ID NO: 6 and CH set forth in SEQ ID NO: 47, and a light chain comprising VL set forth in SEQ ID NO: 7 and CL set forth in SEQ ID NO: 58, or (12) A heavy chain comprising VH set forth in SEQ ID NO: 6 and CH set forth in SEQ ID NO: 48, and a light chain comprising VL set forth in SEQ ID NO: 7 and CL set forth in SEQ ID NO: 58; The antibody or antigen-binding fragment thereof according to any one of [1] to [9],

[11] The antibody or antigen-binding fragment thereof may be an scFv, Fab, Fab', (Fab') 2 The antibody or antigen-binding fragment thereof according to any one of [1] to

[10] , wherein the antibody is selected from the group consisting of a chimeric antibody, an Fv fragment, a diabody, a bispecific antibody, a multispecific antibody, a probody, a chimeric antibody, or a humanized antibody, and preferably the antibody is a chimeric antibody or a humanized antibody.

[12] The antibody or antigen-binding fragment thereof according to any one of [1] to

[11] , which is capable of specifically binding to HBsAg, neutralizing the toxicity of HBV, and / or reducing serum levels of HBV DNA and / or HBsAg in a subject.

[13] An isolated nucleic acid molecule encoding the antibody or antigen-binding fragment thereof according to any one of [1] to

[12] , or the heavy chain variable region and / or light chain variable region thereof.

[14] A vector comprising the nucleic acid molecule according to

[13] , which is preferably a cloning vector or an expression vector.

[15] A host cell comprising the nucleic acid molecule according to

[13] or the vector according to

[14] .

[16] A method for producing the antibody or antigen-binding fragment thereof described in any of [1] to

[12] , comprising culturing the host cell described in

[15] under conditions that allow expression of the antibody or antigen-binding fragment thereof, and recovering the antibody or antigen-binding fragment thereof from the cultured host cell culture.

[17] A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of [1] to

[12] and a pharma- ceutical acceptable carrier and / or excipient.

[18] Use of the antibody or antigen-binding fragment thereof described in any of [1] to

[12] or the pharmaceutical composition described in

[17] in the manufacture of a medicament for preventing and / or treating HBV infection or a disease associated with HBV infection (e.g., hepatitis B) in a subject (e.g., a human), neutralizing the toxicity of HBV in vitro or in a subject (e.g., a human), reducing serum levels of HBV DNA and / or HBsAg in a subject (e.g., a human), and / or activating a humoral immune response to HBV in a subject (e.g., a chronic HBV-infected person or a chronic hepatitis B patient).

[19] For use in the prevention and / or treatment of HBV infection or a disease associated with HBV infection (e.g., hepatitis B) in a subject (e.g., a human), for neutralizing the toxicity of HBV in vitro or in a subject (e.g., a human), for neutralizing the toxicity of HBV in a subject (e.g., a human), The antibody or antigen-binding fragment thereof described in any of [1] to

[12] or the pharmaceutical composition described in

[17] , which is used to reduce serum levels of DNA and / or HBsAg and / or to activate a humoral immune response against HBV in a subject (e.g., a chronic HBV-infected person or a chronic hepatitis B patient).

[20] A method for preventing and / or treating HBV infection or an HBV infection-related disease (e.g., hepatitis B) in a subject, neutralizing the toxicity of HBV in a subject (e.g., a human), reducing serum levels of HBV DNA and / or HBsAg in a subject (e.g., a human), and / or activating a humoral immune response to HBV in a subject (e.g., a chronic HBV-infected person or a chronic hepatitis B patient), comprising administering an effective amount of an antibody or antigen-binding fragment thereof described in any of [1] to

[12] , or a pharmaceutical composition described in

[17] to a subject in need thereof.

Claims

1. 1. An antibody or antigen-binding fragment thereof capable of specifically binding to HBsAg, the antibody or antigen-binding fragment thereof binding to HBsAg with higher affinity at neutral pH than at acidic pH, the antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), (1) VH comprising the following three CDRs: HCDR1 as shown in SEQ ID NO: 8, HCDR2 as shown in SEQ ID NO: 9, HCDR3 as shown in SEQ ID NO: 10, and VL comprising the following three CDRs: LCDR1 as shown in SEQ ID NO: 11, LCDR2 as shown in SEQ ID NO: 12, LCDR3 as shown in SEQ ID NO: 13, (2) VH comprising the following three CDRs: HCDR1 as shown in SEQ ID NO: 14, HCDR2 as shown in SEQ ID NO: 15, HCDR3 as shown in SEQ ID NO: 16, and VL comprising the following three CDRs: LCDR1 as shown in SEQ ID NO: 11, LCDR2 as shown in SEQ ID NO: 12, LCDR3 as shown in SEQ ID NO: 13, (3) VH comprising the following three CDRs: HCDR1 as shown in SEQ ID NO: 20, HCDR2 as shown in SEQ ID NO: 21, HCDR3 as shown in SEQ ID NO: 22, and VL comprising the following three CDRs: LCDR1 as shown in SEQ ID NO: 23, LCDR2 as shown in SEQ ID NO: 12, LCDR3 as shown in SEQ ID NO: 13, or (4) VH comprising the following three CDRs: HCDR1 as shown in SEQ ID NO: 17, HCDR2 as shown in SEQ ID NO: 18, HCDR3 as shown in SEQ ID NO: 10, and VL comprising the following three CDRs: LCDR1 as shown in SEQ ID NO: 19, LCDR2 as shown in SEQ ID NO: 12, LCDR3 as shown in SEQ ID NO: 13, An antibody or antigen-binding fragment thereof comprising:

2. The antibody or antigen-binding fragment thereof of claim 1, further comprising a human immunoglobulin framework region, the framework region optionally comprising one or more backmutations from human residues to murine residues.

3. The antibody or antigen-binding fragment thereof is IGHV4-4 * The heavy chain framework region contained in the amino acid sequence encoded by 08 and IGKV1-39 * 2. The antibody or antigen-binding fragment thereof of claim 1, comprising a heavy chain framework region comprised in an amino acid sequence encoded by SEQ ID NO: 1, and wherein the heavy chain framework region and / or the light chain framework region optionally contain one or more backmutations from human residues to murine residues.

4. The VH of the antibody or antigen-binding fragment thereof comprises a VH FR1 set forth in SEQ ID NO:24, a VH FR2 set forth in SEQ ID NO:25, a VH FR3 set forth in SEQ ID NO:26, and a VH FR4 set forth in SEQ ID NO:27; The antibody or antigen-binding fragment thereof of claim 1, wherein the VL of the antibody or antigen-binding fragment thereof comprises a VL FR1 set forth in SEQ ID NO:28, a VL FR2 set forth in SEQ ID NO:29, a VL FR3 set forth in SEQ ID NO:30, and a VL FR4 set forth in SEQ ID NO:

31.

5. (1) VH having the sequence shown in SEQ ID NO: 1 and VL having the sequence shown in SEQ ID NO: 2; (2) VH having the sequence shown in SEQ ID NO: 3 and VL having the sequence shown in SEQ ID NO: 2; (3) a VH having the sequence shown in SEQ ID NO: 4 and a VL having the sequence shown in SEQ ID NO: 5; or (4) VH having the sequence shown in SEQ ID NO: 6 and VL having the sequence shown in SEQ ID NO: 7; The antibody or antigen-binding fragment thereof of claim 1 .

6. The antibody or antigen-binding fragment thereof of any one of claims 1 to 5, wherein the antibody or antigen-binding fragment thereof further comprises a constant region derived from a human immunoglobulin.

7. The antibody or antigen-binding fragment thereof of claim 6, wherein the heavy chain of the antibody or antigen-binding fragment thereof comprises a human IgG1, IgG2, IgG3 or IgG4 heavy chain constant region and the light chain of the antibody or antigen-binding fragment thereof comprises a human κ or λ light chain constant region.

8. The antibody or antigen-binding fragment thereof of claim 6, wherein the antibody or antigen-binding fragment thereof comprises a light chain constant region (CL) as set forth in SEQ ID NO:

58.

9. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 8, wherein the antibody or antigen-binding fragment thereof comprises a mutant of a human IgG1 heavy chain constant region, the mutant having the following substitutions compared to the wild-type sequence from which it is derived: (i) M252Y, N286E, N434Y, or (ii) K326D, L328Y, wherein the above-mentioned amino acid positions are positions according to the Kabat numbering system.

10. The antibody or antigen-binding fragment thereof described in claim 9, wherein the heavy chain constant region is as shown in SEQ ID NO: 47 or 48.

11. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 8, comprising a heavy chain constant region (CH) as set forth in SEQ ID NO:

57.

12. (1) A heavy chain comprising a VH represented by SEQ ID NO: 1 and a CH represented by SEQ ID NO: 57, and a light chain comprising a VL represented by SEQ ID NO: 2 and a CL represented by SEQ ID NO: 58; (2) A heavy chain comprising a VH represented by SEQ ID NO: 1 and a CH represented by SEQ ID NO: 47, and a light chain comprising a VL represented by SEQ ID NO: 2 and a CL represented by SEQ ID NO: 58; (3) A heavy chain comprising VH set forth in SEQ ID NO: 1 and CH set forth in SEQ ID NO: 48, and a light chain comprising VL set forth in SEQ ID NO: 2 and CL set forth in SEQ ID NO: 58; (4) A heavy chain comprising VH set forth in SEQ ID NO: 3 and CH set forth in SEQ ID NO: 57, and a light chain comprising VL set forth in SEQ ID NO: 2 and CL set forth in SEQ ID NO: 58; (5) A heavy chain comprising VH set forth in SEQ ID NO: 3 and CH set forth in SEQ ID NO: 47, and a light chain comprising VL set forth in SEQ ID NO: 2 and CL set forth in SEQ ID NO: 58; (6) A heavy chain comprising VH set forth in SEQ ID NO: 3 and CH set forth in SEQ ID NO: 48, and a light chain comprising VL set forth in SEQ ID NO: 2 and CL set forth in SEQ ID NO: 58; (7) A heavy chain comprising VH set forth in SEQ ID NO: 4 and CH set forth in SEQ ID NO: 57, and a light chain comprising VL set forth in SEQ ID NO: 5 and CL set forth in SEQ ID NO: 58; (8) A heavy chain comprising VH set forth in SEQ ID NO: 4 and CH set forth in SEQ ID NO: 47, and a light chain comprising VL set forth in SEQ ID NO: 5 and CL set forth in SEQ ID NO: 58; (9) A heavy chain comprising VH set forth in SEQ ID NO: 4 and CH set forth in SEQ ID NO: 48, and a light chain comprising VL set forth in SEQ ID NO: 5 and CL set forth in SEQ ID NO: 58; (10) A heavy chain comprising VH set forth in SEQ ID NO: 6 and CH set forth in SEQ ID NO: 57, and a light chain comprising VL set forth in SEQ ID NO: 7 and CL set forth in SEQ ID NO: 58; (11) A heavy chain comprising VH represented by SEQ ID NO: 6 and CH represented by SEQ ID NO: 47, and a light chain comprising VL represented by SEQ ID NO: 7 and CL represented by SEQ ID NO: 58; or (12) A heavy chain comprising VH set forth in SEQ ID NO: 6 and CH set forth in SEQ ID NO: 48, and a light chain comprising VL set forth in SEQ ID NO: 7 and CL set forth in SEQ ID NO: 58; The antibody or antigen-binding fragment thereof of claim 1 .

13. The antibody or antigen-binding fragment thereof may be an scFv, Fab, Fab', (Fab') 2 13. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 12, which is selected from the group consisting of an Fv fragment, a diabody, a bispecific antibody, a multispecific antibody, a probody, a chimeric antibody and a humanized antibody.

14. 14. The antibody or antigen-binding fragment thereof of any one of claims 1 to 13, which is capable of specifically binding to HBsAg, neutralizing HBV toxicity, and / or reducing serum levels of HBV DNA and / or HBsAg in a subject.

15. An isolated nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, or the heavy and light chain variable regions thereof, according to any one of claims 1 to 14.

16. A vector comprising the nucleic acid molecule of claim 15.

17. 17. A host cell comprising the nucleic acid molecule of claim 15 or the vector of claim 16.

18. 18. A method for producing the antibody or antigen-binding fragment thereof of any one of claims 1 to 14, comprising culturing a host cell of claim 17 under conditions allowing expression of the antibody or antigen-binding fragment thereof, and recovering the antibody or antigen-binding fragment thereof from the cultured host cell culture.

19. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 14, and a pharma- ceutically acceptable carrier and / or excipient.

20. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 14 or the pharmaceutical composition according to claim 19 in the manufacture of a medicament for the prevention and / or treatment of HBV infection or hepatitis B in a subject, for neutralizing the toxicity of HBV in vitro or in a subject, for reducing serum levels of HBV DNA and / or HBsAg in a subject and / or for activating a humoral immune response against HBV in a subject.

21. The use described in claim 20, wherein the subject is a human.

22. The use described in claim 20, wherein the subject is a chronic HBV-infected individual or a chronic hepatitis B patient.

23. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 14 or the pharmaceutical composition according to claim 19, for use in the prevention and / or treatment of HBV infection or hepatitis B in a subject, for use in neutralizing the toxicity of HBV in vitro or in a subject, for use in reducing serum levels of HBV DNA and / or HBsAg in a subject, and / or for use in activating a humoral immune response against HBV in a subject.

24. The antibody or antigen-binding fragment thereof or pharmaceutical composition described in claim 23, wherein the subject is a human.

25. The antibody or antigen-binding fragment thereof or pharmaceutical composition described in claim 23, wherein the subject is a chronic HBV-infected individual or a chronic hepatitis B patient.

Images